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 Glioblastoma is an aggressive form of brain cancer with a five-year survival rate 
after diagnosis of less than 6%. More efficacious treatments are needed to improve 
patient prognosis. Very long-chain acyl-CoA synthetase (ACSVL3) is not detected in 
healthy glial cells, but is highly expressed in gliomas. Knockout of ACSVL3 in 
glioblastoma cells in culture decreases tumorigenicity and disrupts growth-factor induced 
cell signaling. However, the mechanism through which ACSVL3 promotes malignancy is 
not known. To address this question, lipid-based post-translational modifications were 
studied in wild-type and ACSVL3-knockout glioblastoma lines in cell culture. No 
significant differences were found in levels of protein palmitoylation or GPI anchors 
between wild-type and knockout cells. However, a global decrease in protein 
stearoylation was observed with ACSVL3 knockout, and mass spectrometry revealed 
several individual proteins that exhibited increased or decreased stearoylation with 
ACSVL3 knockout. From this we conclude that ACSVL3 is partially responsible for 
mediating stearoylation in glioblastoma cells. Next, we searched for inhibitors of 
ACSVL3. Inhibitors are desired both as tools to study the mechanism of ACSVL3-
promoted malignancy and as potential therapeutic agents in glioblastoma. Two methods 
were established to screen for inhibitors of ACSVL3. The first was a small screen of 
known inhibitors of the homologous enzyme ACSVL1. This screen determined whether 
these drugs and compounds inhibited the activation of the 18-carbon fatty acid stearate by 
glioblastoma cells. The second was development of a screen to evaluate the ability of an 
ACSVL3/ACSVL1 hybrid enzyme to uptake fluorescent fatty-acid analogs. In the first 
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screen, the small molecule CB5 was found to greatly inhibit activation of stearate. When 
glioblastoma cells in culture were treated with CB5, the compound slowed the rate of cell 
proliferation, induced differentiation, and decreased β-oxidation of long-chain fatty acids. 
Growth of subcutaneous xenografts produced from U87, but not Mayo-22, glioblastoma 
cells implanted subcutaneously in mice was significantly slowed by CB5 treatment.  We 
conclude that the small molecule CB5 inhibits ACSVL3 activity in vitro and in vivo, and 
ACSVL3 is a promising novel therapeutic target in glioblastoma. The second screen 
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Acyl-CoA synthetases (ACSs) are a class of enzymes that catalyze the conversion 
of fatty acids to fatty acyl-CoA. The first step of this two-step reaction links the 
carboxylic acid group of the fatty acid to the α-phosphate of ATP, forming fatty acyl-
AMP and releasing pyrophosphate. The second step is the formation of a thioester bond 
between the fatty acyl group and the thiol group of coenzyme A, forming fatty acyl-CoA 
and releasing AMP (Berg, 1956). This reaction, referred to as "activation", is outlined in 
the following equation: 
Fatty acid + ATP → Fatty acyl-AMP + PPi 
Fatty acyl-AMP + CoASH → Fatty acyl-CoA + AMP 
Activation of fatty acids is required for fatty acids to participate in nearly all downstream 
metabolic processes, including energy production via β-oxidation, remodeling of the fatty 
acid such as elongation, incorporation into complex lipids for energy storage or 
membrane synthesis, and post- or cotranslational covalent attachment to proteins 
(Watkins, 1997). 
ACSs are conserved throughout all living organisms. In humans, a search of 
genomic data using highly conserved amino acid sequence motifs has revealed 26 ACS 
enzymes (Watkins et al., 2007). These enzymes are grouped into phylogenetic "families" 
that roughly represent the chain length of fatty acids that the family of ACSs is capable of 
activating (Figure 1). The families are short-chain (ACSS), medium-chain (ACSM), 
long-chain (ACSL), very long-chain (ACSVL), and “bubblegum” (ACSBG). These 
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families contain 22 of the 26 human ACSs, and there are four orphan ACSs (ACSF1-4). 
The family names represent the length of fatty acids that they are capable of activating 
rather than their preferred substrate length, and there is overlap in substrates between 
families. For example, members of the ACSVL family activate long-chain fatty acids at a 
higher rate than very long-chain fatty acids (Steinberg et al., 1999). Similarly to the 
ACSVL family, the ACSBG family is capable of activating both long- and very-long 
chain fatty acids (Steinberg et al., 2000; Pei et al., 2003). ACSs differ from one another 
in not only their substrate specificity, but also in their tissue expression and subcellular 






Each ACS has an N-terminal and C-terminal domain with a flexible linker region 
connecting the two domains. There are two conserved motifs within the C-terminal 
domain of each ACS in all species, called Motifs I and II (Watkins et al., 2007). Motif I 
is a 10-residue AMP-binding domain that is conserved within many AMP-binding 
enzymes. Motif II is a 35-residue motif containing the proposed fatty acid binding 
“signature motif” described by Black et al. (1997). In the center Motif II is an arginine 
residue that is especially invariant, and is found in all known ACSs in all species except 
Figure 1: Phylogenetic tree of human ACS proteins 
 
Full-length amino acid sequences of the longest isoform of each protein were used in 
phylogenetic analysis. ACS families are identified in brackets. Newick tree format was 
determined with European Bioinformatics Institute online tools (McWilliam et al., 




for human ACSBG2, where it is replaced with a histidine residue (Pei et al., 2006). 
Mutation of this arginine (or histidine in the case of ACBG2) renders the enzyme 
catalytically dead (Black et al., 1997).  
 
Very long-chain acyl-CoA synthetase 3 (ACSVL3) and its role in cancer 
The six human ACSVL enzymes share 37–59% sequence identity (Watkins et al., 
2007). The last member of the ACSVL family to be characterized was ACSVL3 (gene 
name: SLC27A3). Historically, the ACSVL family has also been called fatty acid 
transporter proteins (FATP) because they were initially discovered due to their ability to 
transport the long-chain fatty acid analogue C1-BODIPY-C12 into cells (Schaffer and 
Lodish, 1994). In mammals, each enzyme has an ACSVL and a FATP designation. It is 
not yet known whether they aid in the physical transport of fatty acids through the cell 
membrane, or “trap” fatty acids that diffuse across the membrane in the cell by 
converting them to their CoA derivatives. ACSVL3 is also known as FATP3, but 
although it has demonstrable ACS enzyme activity, there is no evidence that it functions 
as a fatty acid transport protein (Pei et al., 2004).  
ACSVL3 is highly expressed in the adrenal gland, ovaries, and testes, and is 
expressed in lower levels in the brain, spinal cord, and lungs in adult mice (Pei et al., 
2004). However, ACSVL3 is expressed highly in embryonic mouse brain tissue, and 
expression decreases continuously from embryonic day 14 to postnatal day 15. ACSVL3 
has also been found in human neural stem cells, indicating that the enzyme may be play a 
role in the development of the central nervous system (Maekawa et al., 2015). In adult 
mouse and human brain tissue, ACSVL3 is expressed in neurons but not glial cells (Pei et 
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al., 2004; Pei et al., 2009). In humans, ACSVL3 is also expressed in pancreas, stomach, 
aorta, and spleen tissue (Pei et al., 2013). Its expression along the digestive tract may 
reflect a role metabolizing fatty acids taken up during digestion. Within cells, ACSVL3 is 
localized to small punctate vesicles; the exact nature of these vesicles remains unknown 
(Pei et al., 2004; Pei et al., 2013). Like other members of the ACSVL family, ACSVL3 
preferentially activates long- and very-long chain fatty acids (Pei et al., 2013).  
While ACSVL3 is undetectable in healthy adult glial cells, histochemical analysis 
showed that it is abundant in malignant gliomas (Pei et al., 2009). To investigate the 
relevance of this observation, our laboratory began investigating cell culture models of 
glioma. When ACSVL3 was knocked down using RNA interference (RNAi) in the 
highly tumorigenic U87 human glioblastoma cell line and tumor cells derived from Mayo 
22 glioblastoma xenografts, the rate of cell proliferation slowed dramatically, and fewer 
colonies formed in soft agar (a measure of tumorigenicity). Knockdown of ACSVL3 also 
disrupted Akt signaling, an important signaling pathway supporting tumorigenicity in 
glioma (Kapoor and O’Rourke, 2003) and in U87 cells (Pei et al., 2009). ACSVL3 is also 
increased in glioblastoma stem cell neurosphere cultures and its expression decreased 
after differentiation of these cells into astrocytes or neurons (Sun et al., 2014). 
Conversely, ACSVL3 knockdown led to an increase in markers of differentiation, 
indicating that ACSVL3 supports a cancer stem cell phenotype in glioma. When 
xenografts formed from U87 cells by implantation in immunocompromised mice, fewer 
and smaller tumors grow from U87 cells if ACSVL3 has been knocked out (Kolar, 2016).  
There is evidence that ACSVL3 plays a similar role in lung cancer (Pei et al., 
2013). As was seen in glioma, ACSVL3 is highly expressed in many different types of 
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lung tumors, while it is only moderately expressed in bronchial epithelial cells in healthy 
lung tissue. RNAi knockdown of ACSVL3 also led to decreased cell proliferation and 
colony formation in soft agar in cell lines derived from lung tumors. Treatment of 
xenograft tumors derived from epithelial lung carcinoma with the anti-cancer agent 
fenretinide resulted in lower expression of Acsvl3 mRNA (Durante et al., 2014).  
 
Lipid metabolism alterations observed in cancer 
As ACSs are central to most aspects of lipid metabolism, it is unsurprising that 
other ACSs have been implicated in various cancers. Many of these are long-chain ACSs. 
A tumor suppressor microRNA called miR-205 that targets ACSL1 is downregulated in 
hepatocellular carcinoma, leading to increased ACSL1 (Cui et al., 2014). ACSL4 (a.k.a. 
Fatty acid-CoA ligase 4 [FACL4]) is upregulated in hepatocarcinoma and sometimes in 
certain breast cancers, and in both cases its expression is correlated with cell proliferation 
and survival (Hu et al., 2008; Wu et al., 2013). ACSL5 (a.k.a acyl-CoA synthetase 5 
[ACS5]) is downregulated in epithelial cells in small intestinal adenomas and 
adenocarcinomas (Gassler et al., 2013), but upregulated in some malignant gliomas, 
where it is also linked to proliferation (Yamashita et al., 2000). The short-chain ACS 
protein ACSS2 (a.k.a. acetyl-CoA synthetase 2) is upregulated in some tumors. ACSS2 
activates acetate that is used for energetic consumption and lipid synthesis, promoting 
cell survival in hypoxia and metabolically stressed, low-lipid environments (Yoshii et al., 
2009, Schug et al., 2015).  
  Downstream of activation by ACSs, nearly all uses of fatty acids within cells are 
known to be disrupted in some way in tumor cells. In general, the production of many 
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types of lipids is upregulated, allowing tumor cells to proliferate rapidly and adapt to 
various conditions. Much of this increased production can be traced back to dysregulation 
of the sterol regulatory element binding proteins (SPREBPs). These transcription factors 
control most fatty acid metabolic processes within the cell, activating transcription of the 
necessary enzymes only when lipid synthesis is required to maintain homeostasis. 
SREBP1 (isoforms 1a and 1c) mainly regulates fatty acid, phospholipid, and 
triacylglycerol (TAG) synthesis, and SREBP2 regulates cholesterol synthesis (Eberlé et 
al., 2014). The SREBPs are overexpressed in many cancers and overactivated in others, 
leading to increased expression of enzymes involved in lipid synthesis (Menendez and 
Lupu, 2007; Shao and Espenshade, 2012). 
De novo synthesis of fatty acids is activated in many tumors formed from tissues 
that do not typically synthesize fatty acids (Menendez and Lupu, 2007). The expression 
of ATP citrate lyase, acetyl-CoA carboxylase, and fatty acid synthase, the main enzymes 
in fatty acid synthesis, are upregulated in these tumors. Expression of the elongase 
ELOVL7 is also overexpressed in prostate cancer, creating an abundance of long-chain 
fatty acids (Tamura et al., 2009). Newly synthesized fatty acids can be activated and 
incorporated into TAG and stored in lipid droplets, which are found in increased numbers 
in cancer cells (Murphy, 2001). Other activated fatty acids are incorporated into 
phospholipids and become cell or organelle membranes. The upregulation of enzymes 
involved in the synthesis of phosphatidylcholine (PC), such as choline kinase, and 
phosphatidylethanolamine (PE), the two major lipids found in cell membranes, indicates 
that this process is also increased in tumors (Janardhan et al., 2006; Cheng et al., 2016).  
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  Some complex lipids are upregulated in cancer, while others are 
downregulted.  Activated fatty acids can also be incorporated into sphingosine and 
ceramide (an acylated sphingosine). Ceramide has been identified as a tumor suppressor, 
and the enzymes required for its synthesis are often lowered in tumors (Morad and Cabot, 
2013). Conversely, sphingosine kinases 1 and 2 and their product sphingosine-1-
phosphate is commonly upregulated in cancer (Pyne et al., 2014). Acetyl-CoA, 
originating from either the citric acid cycle or the breakdown of fatty acids, can be 
incorporated into cholesterol, another lipid that has been shown to be accumulated in 
many types of cancer (Kuzu et al., 2016). Cholesterol synthesis is upregulated in tumor 
cells (Kuzu et al., 2016), and statins (drugs blocking cholesterol synthesis) decrease 
tumorigenesis in many cancerous cell lines (Pisanti et al., 2014).  
Another fate of activated fatty acids is post-translational modification of proteins. 
There is an increase in N-myristoyltransferase activity, the enzyme that catalyzes 
myristoylation (the attachment of a 14-carbon fatty acid) in human colorectal cancer, 
gallbladder carcinoma and brain tumors (Selvakumar et al., 2007). Many palmitoyl 
acyltransferases, the enzymes that attach the 16-carbon fatty acid, palmitate, to proteins, 
function as either tumor suppressors or oncogenes in various cancers (Resh, 2016). A 
number of enzymes that undergo farnesylation, the covalent attachment the cholesterol 
intermediate farnesyl, have been found to be upregulated or mutated in cancer as well 
(Novelli and D’Apice, 2012). 
 Finally, activated fatty acids can be degraded by β-oxidation to produce energy. 
Prostate tumors exhibit overexpression of enzymes used in β-oxidation (Zha et al. 2005), 
and β-oxidation has been found to aid cell survival in cancers originating from tissue 
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types that do not typically perform β-oxidation, such as leukemia, breast cancer, and 
ovarian cancer (Samudio et al., 2010; Camarda et al., 2016; Nieman et al., 2011). 
 
Changes in lipid metabolism promote cancer phenotypes 
These aberrancies in lipid metabolism contribute in many ways to cancerous 
phenotypes. First, the abundance of phospholipids and cholesterol can be used for 
membrane synthesis. Because of the rapid cell proliferation that is the hallmark of cancer, 
large amounts of lipids are needed to synthesize the nascent cell membranes, especially 
the phospholipids PC and PE. Often, membrane composition is higher in saturated fatty 
acids and cholesterol in tumor cells, reflecting the increased availability of these lipids 
(Rysman et al., 2010). This leads to a reduction of membrane fluidity since saturated 
lipids pack more tightly (Ollila et al., 2007). The changes in membrane dynamics also 
appear to promote survival by protecting cancer cells from both peroxidative stress and 
chemotherapeutic agents (Rysman et al., 2010). 
The increased lipid droplets and β-oxidation seen in many tumor cells can provide 
the cells with energy in times of metabolic stress. Lipid droplets aid survival in hypoxia 
and nutrient deficiency due to hypovascularization (Koizumi and Miyagi, 2016). Also, 
there is evidence that the upregulation of β-oxidation in intra-abdominal tumors allows 
the cancer cells to use lipids from neighboring adipocytes as a fuel source. This was 
observed in vitro when ovarian cancer cells were cultured with adipocytes, which 
induced lipolysis in adipocytes and β-oxidation in cancer cells (Nieman et al., 2011). 
Many signaling pathways activated in cancer involve lipids. The increased 
cholesterol in the plasma membrane leads to increased lipid raft domains that act as 
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signaling platforms. Lipid rafts harbor many receptor tyrosine kinases, such as growth 
factor receptors, and thus increased lipid rafts results in increased signaling through 
survival pathways such as the Akt signaling pathway. (Mollinedo and Gajate, 2015) Also 
critical to Akt signaling is another lipid, phosphatidylinositol (PI). In cancer, the 
conversion of PI to phosphatidylinositol-3,4,5-trisphosphate (PI(3,4,5)P3) is increased 
(Fresno Vara et al., 2004). PI(3,4,5)P3 recruits Akt to the inner leaflet of the plasma 
membrane, allowing Akt to be activated by phosphorylation. Sphingosine-1-phosphate 
promotes cell proliferation and tumor growth by deregulating the cell cycle and 
promoting inflammation (Pyne et al., 2014). Finally, the lipid-based post-translational 
modifications of proteins act as signals that contribute to cancer phenotypes. For 
example, palmitoylation of human integrin β4, a transmembrane receptor that aids 
extracellular matrix adhesion, correlates with invasiveness in breast cancer cells 
(Coleman et al., 2015). Finally, farnesylation of Ras is required for the its association 
with the inner leaflet of the plasma membrane, where it is further modified to its 
biologically active form and promotes proliferation in response to growth factors. Ras is 
often mutated in cancers to an always-active state, which allows uncontrolled cell growth 
and proliferation (Rowinsky et al., 1999).  
Inhibitors of many lipid-metabolizing enzymes have been demonstrated to slow 
proliferation or induce apoptosis of cancer cells in vitro and in mouse models. Triacsin C, 
a nonspecific inhibitor of many long-chain acyl-CoA synthetases, induces apoptosis in 
glioma cells and improves the prognosis of mice bearing xenografts in conjunction with 
chemotherapy (Mashima et al., 2009). The fatty acid synthase inhibitor cerulenin induces 
apoptosis in murine colorectal cancer cell lines and reduces the number and sizes of liver 
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metastatic colorectal tumors in mice (Merata et al., 2010). Inhibition of carnitine 
palmitoyl transferase 1 with etoximir, which prevents fatty acids from shuttling into 
mitochondria for β-oxidation, reduces viability in human glioblastoma cells in culture 
(Pike et al., 2011). The farnesyl transferase inhibitor Lonafarnib, as well as statins,have 
been examined in clinical settings as cancer therapeutics. Some tumors responded well to 
Lonafarnib in Phase I and II clinical trials, although no improvement in survival was 
found in Phase III trials (Morgillo and Lee, 2006). A meta-analysis of 41 studies studying 
revealed that statin use decreased mortality in cancer patients, including those suffering 
from colorectal, prostate, breast, and other cancers (Zhong et al., 2015).  
Currently, cancer treatments do not target lipid metabolism pathways directly. 
Targeting the many upregulated and overactive enzymes that promote cancer phenotypes 
is a promising therapeutic strategy.  
 
Glioblastoma  
The most common primary CNS tumors are gliomas, accounting for 78% of 
malignant CNS tumors (Ostrom et al., 2016). Gliomas include tumors originating from 
all glial cells, but are named after the type of cell with which they share histological 
features rather than the cell of origin. Gliomas include astrocytomas, oligodendrogliomas, 
ependymomas, and mixed gliomas. Instead of staging, gliomas and other CNS tumors are 
categorized by grades I-IV defined by the World Health Organization (Louis et al., 
2016). Low grade gliomas (grades I and II) are more differentiated and have higher 
survival rates, while high grade gliomas (III and IV) are undifferentiated, grow rapidly, 
are invasive, and have lower survival rates. Glioblastomas (GBM; a.k.a glioblastoma 
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multiforme) are grade IV astrocytomas. They are the most common form of glioma, 
accounting for 55.4% of glioma cases, and 46.6% of all primary malignant brain tumors 
(Ostrom et al., 2016). Prognosis for patients is very low, with a 5-year survival rate of 
only 5.5%. There were 12,150 new cases of GBM diagnosed in the United States in 2016, 
with 12,390 expected diagnoses in 2017. 
An important tool in GBM research is the U87MG (U87) cell line. This cell line 
has been mentioned in over 2,000 publications since it became available in 1966. 
Originally, this cell line was isolated from a 44-year-old Caucasian male with a grade IV 
astrocytoma. However, recent genetic analysis shows that the current cell line used is 
different from the purported tumor of origin (Allen et al., 2016).  Fortunately, modern 
U87 cells are most likely still glioblastoma. The characterization of ACSVL3 in cancer 
was performed largely in U87 cells (Pei et al., 2009; Sun et al., 2014). Our lab has 
generated both ACSVL3 knockout and stable knockdown U87 cells in order to further 
study its role in tumorigenesis.  
 
Thesis Aims 
As discussed earlier, the acyl-CoA synthetase ACSVL3 is aberrantly expressed in 
human gliomas. Knockdown of ACSVL3 decreases cell proliferation and tumorigenicity 
in glioblastoma cells in culture and xenografts. While ACSVL3 appears to be critical to 
the cancer phenotype of glioma cells, it is not known how the enzyme acts to promote 
tumorigenesis. Since acyl-CoA synthetases are central to lipid metabolism, there are 
many pathways that ACSVL3 might affect. One of the major roles of lipids that requires 
activation by an ACS is post-translational modifications of proteins. In this thesis, I 
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discuss the role of ACSVL3 in two types of post-translational modifications: acylation of 
proteins with the long-chain fatty acids palmitate and stearate, and the attachment of 
glycosylphosphatidylinositol (GPI) anchors to proteins. 
The prognosis of patients diagnosed with GBM is very poor even with aggressive 
treatment. New, more efficacious treatments are needed, and targeting lipid metabolism is 
a promising new direction. Since ACSVL3 is not expressed in healthy glial cells but is 
abundant in glioma cells, it is an attractive therapeutic target. In this thesis, I discuss two 
screening mechanisms used to identify inhibitors of ACSVL3 activity. I also show the 
effects of one robust inhibitor of ACSVL3 on U87 cells in culture and in mice bearing 









ACSVL3 is an attractive therapeutic target for glioma. ACSVL3 is not expressed 
in healthy glial cells, but it is highly expressed in glioblastomas (Pei et al., 2009). 
Knockdown of ACSVL3 in glioblastoma cells led to slower growth rate, decreased 
tumorigenicity in vitro and in xenograft models, and disrupted Akt signaling. We 
hypothesized that inhibition of ACSVL3 activity with a drug or chemical inhibitor would 
have a similar anti-tumorigenic effect. We developed a two-prong approach to identify 
ACSVL3 inhibitors. First, inhibitors of the homologous enzyme ACSVL1 were screened 
for inhibition of ACSVL3. Second, a fluorescence-based high-throughput screen was 
developed to screen chemical libraries for inhibition of ACSVL3.  
A homologue of ACSVL3 is another very long-chain acyl-CoA synthetase, 
ACSVL1 (a.k.a. fatty acid transport protein 2 [FATP2]). Like ACSVL3, ACSVL1 
converts both long- and very long chain fatty acids to their CoA derivatives. ACSVL1 is 
expressed highly in liver and kidney tissue and localizes to peroxisomes and the 
endoplasmic reticulum (Steinberg et al., 1999). In addition to its enzyme activity, 
ACSVL1 facilitates the transport of fluorescent or radiolabeled fatty acids across the 
plasma membrane and into the cell matrix. Although it is not known for certain whether 
ACSVL1 physically transports the fatty acids or simply traps them in the cell by 
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converting them to their CoA derivatives, it is assumed that catalytic activity is required 
for fatty acid uptake (Jia et al., 2007; Falcon et al. 2010). In addition to being stored in 
cells, uses for long- and very long-chain fatty acids activated and/or transported by 
ACSVL1 include phosphatidylinositol synthesis (Melton et al., 2011) and sphingosine 1-
phosphate metabolism (Ohkuni et al., 2013).  
The C-terminal catalytic domains of ACSVL1 and ACSVL3 are highly 
homologous (Figure 2). These domains bind both fatty acids and ATP, and thus are 
responsible for the conversion of long- and very-long chain fatty acids to their acyl-CoA 
derivatives. However, the smaller, N-terminal domains of ACSVL1 and ACSVL3 are 
significantly different. While the exact purpose of the N-terminal domains is not known, 
it is assumed to be a regulatory domain, possibly involved in subcellular location 





Figure 2: Sequence alignment of ACSVL3 and ACSVL1 
The sequences of the homologous enzymes ACSVL3 (top row) and ACSVL1 (bottom 
row) are shown. Regulatory and catalytic domains are denoted. The regulatory domain 
of ACSVL3 is 110 bp longer than the regulatory domain of ACSVL3.  The two 
regions in red are necessary for catalysis. The first region (referred to as Motif I) is an 
AMP biding domain, and the second (Motif II) is the proposed fatty acid binding 
“signature motif”. Sequence alignment was performed using Clustal-W at EMBL-EBI 
(Larkin et al., 2007; Goujon et al., 2010). 
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Black and DiRusso exploited the fatty acid transport property of ACSVL1 to 
develop a high-throughput screen for inhibitors of this enzyme (U.S. Patent No. 
7,070,944, 2006). They produced a strain of yeast deficient in both fatty acid uptake and 
acyl-CoA synthetase activity, and exogenously expressed human ACSVL1.  ACSVL1-
overexpressing cells took up C1-BODIPY-C12, a fluorescent long chain fatty acid analog, 
while the deficient cells did not. Using fatty acid uptake as a surrogate for acyl-CoA 
synthetase activity, over 100,000 drugs and compounds were screened (Li et al., 2008; 
Sandoval et al., 2010). Yeast cells were treated with compounds from three libraries: the 
SpectrumPlus library from MicroSource Discovery Systems Inc., the NCI Diversity Set 
Compound Library and the ChemBridge Corporation compound library. The yeast cells 
were treated with C1-BODIPY-C12 and trypan blue after incubation with compounds. 
Trypan blue quenched extracellular fluorescence, so only fluorescence from C1-
BODIPY-C12 taken up by the cells was measured. The screen identified several 
compounds that inhibited the uptake of C1-BODIPY-C12. Secondary screening eliminated 
autofluorescent compounds, compounds that quenched C1-BODIPY-C12 fluorescence, 
and compounds that permeabilized the cell membrane. The SpectrumPlus screen revealed 
28 ACSVL1 inhibitors, many of which were tricyclic, phenothiazine-derived 
antipsychotic drugs. The Diversity Set/Chembridge screen revealed 216 ACSVL1 
inhibitors, which were clustered into 5 structural classes. Inhibition of uptake of fatty 
acids in human cell lines was characterized using a compound representative of each 
structural class. 
Since ACSVL1 is homologous to ACSVL3 throughout the catalytic domain, we 
expected that the identified inhibitors of ACSVL1 might also inhibit the acyl-CoA 
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synthetase activity of ACSVL3. Due to the aberrant expression of ACSVL3 in gliomas, 
we hypothesized that an inhibitor could act as a therapeutic agent. We assessed several of 
the identified drugs from the SpectrumPlus screen (triflupromazine, phenazopyridine, 
chlorpromazine, emodin, and perphenazine) and four of the compounds characterized 
following the Diversity Set/Chembridge screen (referred to as CB2, CB5, CB6, and 
CB16.2) for their effect on the acyl-CoA synthetase activity of ACSVL3 in vitro. We 
found that many of these drugs and compounds inhibited ACSVL3 activity.  
The most potent inhibitor of ACSVL3 activity was a compound from 
ChemBridge Corporation compound library, 2-benzyl-3-(4-chlorophenyl)-5-(4-
nitrophenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one, referred to here as CB5 (a.k.a. 
Grassofermata). CB5 was also one of the most potent ACSVL1 inhibitors and was found 
to robustly inhibit the uptake of oleic acid in Caco-2 cells (Sandoval et al., 2010). CB5 
has been recently found to prevent palmitate-induced lipotoxicity and apoptosis in cells in 
culture and inhibit fatty acid uptake across the intestinal epithelium in mice (Saini et al., 
2015).  
We treated U87 human glioblastoma cells with CB5, and found that it decreased 
β-oxidation of long-chain and very long chain fatty acids. CB5 also dramatically slowed 
the growth rate of U87 cells, decreased invasiveness, and induced a unique morphology 
and the expression of a marker of differentiation. When given to mice bearing xenograft 
tumors, CB5 slowed growth and eventually reduced the size of tumors formed from U87 
cells, although it did not have a significant effect on another human glioma xenograft 
model, Mayo-22. Based on our results, CB5 appears to be both a useful tool for 
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understanding the role of ACSVL3 in tumorigenesis and a potential therapeutic drug for 
some glioblastomas.  
In this study we also introduce a new fluorescence-based screen to identify other 
inhibitors of ACSVL3. Based on the screen described by Li et al. (2008), this screen 
assesses the uptake of C1-BODIPY-C12 in Cos-1 cells expressing a hybrid enzyme called 
ACSVL1/3. This enzyme is a domain-swapped chimera comprised of the regulatory 
domain of ACSVL1 and the catalytic domain of ACSVL3. This domain swap couples the 
ability to uptake C1-BODIPY-C12 (which wild-type ACSVL3 cannot do) with the acyl-
CoA synthetase activity of ACSVL3. Here we use this screening method as a method to 
compare the effects of identified ACSVL1 inhibitors on the uptake of C1-BODIPY-C12 
on the hybrid ACSVL1/3.  
 
Materials and Methods 
 
Cell culture 
    U87MG and Cos-1 cells were obtained from American Type Culture Collection. Both 
lines were cultured in Dulbecco's Modified Eagle's Medium (DMEM) with 10% fetal 
bovine serum (FBS). GM9503 skin fibroblasts (healthy 10 year old male) were obtained 
from the Coriell Institute (Camden, NJ). They were cultured in Minimum Essential 






Drugs and compounds 
Table 1 lists the formula of the drugs and compounds added to various assays, 
listed by the name they are referred to throughout this chapter. 
Table 1: Systematic names of drugs and compounds included in assays 
 



















Generation of ACSVL3-KO U87 cell line 
The ACSVL3-knockout (KO) U87 was produced with the CompoZr Knockout 
Zinc Finger Nuclease plasmids designed and created by Millipore Sigma. The forward 
and reverse sequences target genomic DNA before and after the second exon in the 
ACSVL3 sequence. (Forward: 5’-TGTGCTTTCCCACCCTTCTA-3’, reverse: 5’-
AGGTGAGGAGACTGGGAGT-3.) Plasmids were transfected into WT U87 cells via 
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Fugene (Promega) and harvested using trypsin after 48 hours. Cells were counted with a 
hemocytometer and plated into 96-well plates at an average density of 0.9 cells/well with 
the goal of creating clones generated from a single cell. Clones were selected with 
hygromycin and expanded. ACSVL3 knockout was previously verified with PCR of both 
genomic DNA and cDNA generated from mRNA and mass spectrometry (Kolar, 2016). 
Immunofluorescence and western blotting as described below were used to assess 
ACSVL3 knockout. A 1:10 dilution of culture media from hybridoma cells producing 
monoclonal α-ACSVL3 antibody was used as the primary antibody source for both 
methods. Secondary antibodies used were goat α-mouse IgG-HRP (1:8,000 dilution in 
milk solution, Santa Cruz Biotechnology) for Western blotting, and goat-α-mouse Cy3 
(1:150 dilution  in PBS/BSA, Jackson ImmunoResearch).  
 
Acyl-CoA Synthetase Activity Assays 
To harvest cells, 10 cm plates of cells in culture were treated with 1 mL of 0.25% 
trypsin to release cells from the plates. The suspension of cells was pelleted by 
centrifugation and then washed twice with phosphate-buffered saline (PBS) containing a 
protease inhibitor cocktail. The pellets were resuspended in buffer containing 0.25 M 
sucrose, 1 mM Tris-HCl pH 7.5, and 1 mM EDTA (STE buffer). Protein concentration 
was measured using the assay described by Lowry et al. (1951). 
Acyl-CoA synthetase assays were adapted from the protocol described by 
(Watkins et al., 1991). A working solution was made containing 1 nmol of radiolabeled 
[1-
14
C]palmitic, stearic, behenic, or lignoceric acid (Moravek) and 4 nmol unlabeled 
corresponding fatty acid (Millipore Sigma) per 50 μL in benzene. For each drug in both 
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WT and ACSVL3-KO U87 cell lines, duplicate samples were assayed. 50 μL of the 
working solution was added to 13x100 mm glass test tubes and dried down under 
nitrogen gas. The fatty acids were solubilized in 50 µL 10 mg/mL α-cyclodextrin in 10 
mM Tris (pH 8.0). The tubes were sonicated in a water-bath sonicator for 2 minutes at 
37°C and then incubated in a 37°C water bath shaker for 30 minutes to fully solubilize 
the fatty acids. Next, cell suspensions containing 30 μg of total protein in 50 μL (or 48 μL 
for assays containing drugs or compounds) of STE were added to each tube. For 
synthetase assays containing drugs or compounds, 2 μL drug or compound was then 
dissolved in DMSO (final assay concentration of 80, 10, 1 or 0.1 μM) and mixed into the 
suspension. Finally, 150 μL of a reaction mix was added to each tube, leading to final 
assay concentrations of 40 mM Tris-CL (pH 8.0), 10 mM ATP, 1 mM MgCl2, 0.2 mM 
CoA, and 0.2 mM dithiothreitol (DTT). The tubes were vortexed and incubated in a 37°C 
water bath shaker for 20 minutes. The reaction was stopped with 1.25 mL modified 
Dole’s solution (40:10:1 Isopropanol: Heptane: 2N H2SO4). The tubes sat at 20°C for at 
least 20 minutes, and then centrifuged at 831g at 20°C for 10 minutes to pellet debris. 
Supernatants were removed for work-up. 
Next, fatty acyl-CoA derivatives were extracted from unreacted fatty acids via 
Dole’s method (Dole, 1956). 0.75 mL heptane and 0.5 mL H2O were added to each 
sample. Samples were vortexed, and the upper organic phase was aspirated. 0.75 mL 
heptane was added again, followed by another vortex and aspiration of the upper organic 
phase. A third 0.75 mL heptane was added. Samples were vortexed and then centrifuged 
at 831g at 20°C for 1 minute prior to aspiration of the upper organic phase. The lower 
aqueous phase from each sample was transferred to a scintillation vial and 5 mL of 
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Budget-Solve HFP was added. Radioactivity of samples was measured by liquid 
scintillation counting. 
The output from the counter was in disintegrations per minute (DPM). The DPMs 
from duplicate samples were averaged and the average DPMs of the blank sample were 
subtracted. An aliquot of the stearic acid working solution was counted to determine 
DPMs/nmol (specific activity), and results were converted to nmol stearic acid activated 
per 20 minutes per mg protein. 
 
Generation and characterization of a domain-swapped ACSVL1/3 hybrid 
The N-terminal domain of ACSVL1 and the enzymatic C-terminal domain of 
ACSVL3 were cloned together to form a hybrid enzyme. Sequence and ligation 
independent cloning (SLIC) was used as described by Li and Elledge (2012) to produce 
chimeric cDNA from the sequence of ACSVL3. The nucleotides coding for amino acids 
1-210 of ACSVL3 were replaced with those coding for amino acids 1-100 of ACSVL1. 
The sequence was cloned into the mammalian expression vector pcDNA3 (Invitrogen) 
and transfected into COS-1 cells with FuGENE6 (Promega). Transfected colonies 
resistant to G418 were selected. The resulting hybrid enzyme is referred to as 
ACSVL1/3. 
pcDNA3 containing the sequences of ACSVL3 and ACSVL1  as well as the 
empty vector were all transfected into COS-1 cells for comparison and characterization of 
ACSVL1/3. COS-1 cells stably expressing each construct were plated onto glass 
coverslips and allowed to attach in normal media. The media was aspirated and replaced 
with serum-free media for 30 minutes, and then incubated with 2 μM 4,4-difluoro-5-
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methyl-4-bora-3a,4a-diaza-s-indacene-3-dodecanoic acid (C1-BODIPY-C12; Thermo 
Fisher Scientific) for 20 minutes. Coverslips were washed with PBS and visualized via 
fluorescence microscopy to assess C1-BODIPY-C12 uptake.  
To quantify C1-BODIPY-C12 uptake, COS-1 cells stably expressing ACSVL3, 
ACSVL1, ACSVL1/3, and the empty vector pcDNA3 were plated into opaque-walled 
96-well plates and allowed to grow to confluence under normal conditions. The culture 
media was removed and replaced with serum-free DMEM for serum starvation. After 1 
hour, the serum-free media was replaced with DMEM containing 5 μM C1-BODIPY-C12, 
5 μM bovine serum albumin (BSA), and 1.97 mM trypan blue. The plates were incubated 
for 20 minutes at 37°C and 5% CO2. The trypan blue quenches fluorescence of 
extracellular C1-BODIPY-C12 that is not uptaken by cells. Fluorescence of uptaken C1-
BODIPY-C12 was quantitated using a SpectraMax M5 microplate reader.  
 
C1-BODIPY-C12 uptake inhibition in Cos-1 cells expressing ACSVL1/3 
Cos-1 cells expressing the ACSVL1/3 hybrid were plated into opaque-walled 96-
well plates and grown and serum-starved as described above. The serum-free media was 
removed and replaced with DMEM containing 5 μM C1-BODIPY-C12 , 5 μM BSA, 1.97 
mM trypan blue, and either an ACSVL1 inhibitor or the equivalent volume of DMSO. 
Duplicate wells were set up, and each of the following concentrations of each inhibitor 
was tested: 0.1, 0.5, 1, 5, and 10 μM (dissolved in DMSO and diluted 1:1000 in the 
assay). The plates were incubated for 20 minutes. Fluorescence was quantitated using a 




Cell growth studies with CB5 
Growth curves of U87 cells treated with 3 μM CB5: 5000 WT or ACSVL3-KO 
U87 cells were seeded into wells of 6-well plates containing DMEM + 10% FBS (U87 
cell culture media) on day 0. On day 1, media was aspirated and replaced with cell 
culture media containing either 3 μM CB5 (1:1000 dilution of 3 mM stock concentration 
in DMSO) or equivalent DMSO only (control). Triplicate wells of each condition were 
harvested via trypsin and counted by hemocytometer on days 3, 6, 9, 12, and 15. Cell 
media and drug/DMSO were refreshed every 3 days. 
Growth response of U87 cells to varying doses of CB5: 5000 WT U87 cells were 
seeded into wells of 6-well plates on day 0. On day 1, triplicate wells were aspirated and 
treated with varying concentrations of CB5 in U87 cell culture media. Concentrations 
used were 1, 1.5, 2 2.5, 3, 3.5, 4, 4.5, 5, 7.5, and 10 μM CB5. CB5 was dissolved into 
DMSO for stock solutions, which were diluted 1:1000 in culture media. Media and CB5 
were refreshed every 3 days. On day 12, all wells were harvested via trypsin and counted 
by hemocytometer.  
Reversion of growth in U87 cells previously treated with CB5: 5000 WT U87 
cells were seeded into 6-well plates on day 0. Three groups were set up: CB5 treatment 
throughout the experiment, CB5 treatment through day 9 followed by DMSO treatment, 
and DMSO treatment throughout the experiment. Cells were treated with 3 μM CB5 or 
DMSO as described above on day 1. On day 9, media from half of the cells treated with 
CB5 was aspirated and replaced with media containing equivalent DMSO for the 
remainder of the experiment. Triplicate wells were harvested via trypsin and counted by 
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hemocytometer on days 9, 12, 15, 18, 21, and 23. Cell media and drug/DMSO were 
refreshed every 3 days. 
 
Imaging U87 cells grown in 3 μM CB5 
5000 WT or ACSVL3-KO U87 cells were seeded onto 3.5 cm plates on day 0. On 
day 1, half were treated with 3 μM CB5 as described earlier and half were treated with 
equivalent DMSO. To assess changes in morphology induced by CB5, cells were imaged 
with using light microscopy with an Axiovert 100 TV microscope (Carl Zeiss) on days 3, 
6, 9, and 12. Cell media and drug/DMSO were refreshed every 3 days. 
 
Fatty acid β-oxidation assay 
WT U87 cells were seeded into 6-well plates and allowed to grow to near 
confluence. For each fatty acid, duplicate blank wells (media only, no cells) were set up 
to serve as extraction controls. Approximately 1.5 hour before the assay, media was 
removed and replaced with 540 μL serum-free DMEM containing 2.2 mM carnitine and 
3 μM CB5 (3 mM stock in DMSO diluted 1:1000 in media) or equivalent DMSO for 
control and blank wells.  Replicate wells were set up to determine protein concentration.  
For the assay, fatty acid working solutions were made containing 20 μM 
radiolabeled [1-
14
C]fatty acid and 80 μM unlabeled fatty acid in benzene. Fatty acids 
assayed were palmitic, stearic, oleic (radiolabeled from Moravek, unlabeled from 
Millipore Sigma), behenic, and lignoceric acid. Working solutions were warmed to 37°C 
in a water bath for 5 minutes, sonicated in a water bath type sonicator for 2 minutes, and 
briefly vortexed. The total working solution needed of each fatty acid was added to a 
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glass test tube and dried down under nitrogen gas. The fatty acids were resolubilized in 
an equivalent volume of 10 mg/mL α-cyclodextrin in 10 mM Tris (pH 8.0). The tubes 
were incubated for 40 min at 37°C in a water bath type sonicator with occasional 
vortexing to optimize solubilization. 60 μL of each solubilized fatty acid was added to 
duplicate wells containing U87 cells treated with CB5, U87 cells treated with DMSO, 
and blank, cell-free wells. Plates were manually shaken gently to mix and incubated at 
37°C for 2 hours. The incubation was stopped by adding 120 μL of ice-cold 18% HClO4 
to each well. Plates were kept at 4°C for 40 minutes. The contents of each well were 
moved to 12x75 mm glass test tubes. 
Water-soluble products of β-oxidation were extracted from unreacted fatty acids 
using a Folch extraction (Folch et al., 1957). 3.75 mL of 1:1 CHCl3:Methanol was added 
to 16x125 mm screw-top test tubes (one per sample). 450 μL of sample was added to 
these tubes which were then vortexed. 1.9 mL CHCl3 was added to the tubes, which were 
again vortexed. 1.2 mL H2O was added to each tube and the samples were vortexed. 
Tubes were centrifuged at 831g for 5 minutes to separate the phases. The upper, aqueous 
phase of each sample was transferred to a scintillation vial. 10 mL of Budget-Solve HFP 
(Research Products International) was added to each vial. The vials were agitated to mix 
contents, and radioactivity was determined by liquid scintillation counting.  
Media from replicate wells that were set up to determine protein concentration 
was aspirated. Wells were washed with PBS and then treated with 400 μL lysis buffer 
comprised of 0.1 M sodium phosphate pH 7.5, 0.15 M NaCl, and X% NP40. The Pierce 
660 nm Protein Assay was used to determine concentration.  
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The output from the counter was in disintegrations per minute (DPM). The DPMs 
from duplicate samples were averaged and the average DPMs of the blank sample were 
subtracted. An aliquot of the stearic acid working solution was counted to determine 
DPMs/nmol (specific activity), and results were converted to nmol stearic acid activated 
per 20 minutes per mg protein. 
 
Immunofluorescence 
Cells were seeded into plates containing glass coverslips. The next day, media 
containing 3 μM CB5 or equivalent DMSO was added. Cells were treated for 9 days. 
Media and drug/DMSO was refreshed every 3 days.  
Coverslips were removed from culture plates and washed 3 times with Dulbecco's 
phosphate-buffered saline (DPBS) containing calcium and magnesium. Cells were fixed 
by incubating the coverslips for 20 minutes in PBS with 3% formaldehyde. Coverslips 
were again washed 3 times with PBS. Cells were permeabilized by incubating for 5 
minutes in 40 μg/mL digitonin in PBS. Coverslips were washed 3 times in PBS again, 
then incubated for 40 minutes in α-GFAP antibody (Dako) diluted 1:5000 in 0.01% BSA 
in PBS. Coverslips were washed 7 times in PBS, then incubated for 40 minutes in Cy3-
linked goat-α-rabbit secondary antibody (Jackson ImmunoResearch) diluted 1:150 in 
0.01% BSA in PBS. Coverslips were again washed 7 times. Coverslips were mounted to 
glass microscope slides (mount solution: 1 mg/mL phenylenediamine and 0.1 M Tris pH 
8.7 in 90% glycerol) and sealed. Cells were visualized by fluorescence microscopy using 





Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was 
used to separate proteins. Protein samples were boiled in sample loading buffer (5X 
stock, final 1X concentrations of 2% SDS, 50 mM Tris, 0.2 mg/mL bromophenol blue, 
5% 2-mercaptoethanol, 12.5 mM EDTA, and 10% glycerol). 20 μg of protein was added 
to each lane of a 10% acrylamide gel prepared by the method of Laemmli (1970). 
Proteins were separated at 100 V, then transferred from the gel to PVDF membrane for 2 
hours in tris-glycine buffer with 20% methanol at 100 V. The PVDF membrane was 
blocked with 10% milk (w/v) in TBST (0.15 M NaCl, 0.05% Tween-20, and 0.01 M Tris, 
pH 7.4) for at least 1 hour. Next, the membrane was incubated in a diluted primary 
antibody solution in 10% milk in TBST for 1 hour, then washed 3 times with TBST. The 
membrane was then incubated in a diluted secondary antibody solution in 10% milk in 
TBST for 1 hour, then again washed 3 times with TBST. The membrane was incubated in 
SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific) 
according to the reagent manual’s instructions and exposed to film to detect signal. The 
primary antibody used was α-GFAP (1:500 dilution in milk solution; Dako). Due to 
unequal loading, β-actin was also detected as a loading control using α-β-actin antibody 
(1:800 dilution in milk solution; Santa Cruz Biotechnology). The secondary antibody 







Treatment of fibroblasts with CB5 
To examine the effect of CB5 on a non-cancerous cell line, human primary 
fibroblast GM9503 cells were treated with the drug for several days. Cells were seeded 
into wells in a 12-well plate at approximately 80% confluency. The next day, duplicate 
wells of cells were treated with the following concentrations of CB5: 1 μM, 3 μM, 6.5 
μM, 10 μM, and DMSO only. Stock solutions of CB5 in DMSO were made for each 
concentration so the dilution into culture media was 1:1000 in each condition. Cells were 
allowed to grow for 5 days and then imaged with an EVOS XL Core Imaging System 
(Thermo Fisher Scientific). Media and drug was refreshed on the 3rd day. 
 
Scratch-wound assay 
Cells were seeded into 6-well plates and allowed to grow to about 80% 
confluence. A 1000 μL pipet tip was used to scratch the cell layer in each well. Scratches 
were imaged immediately after the scratch, 24 hours post-scratch and 48 hours post-
scratch to assess cell growth over the scratch wound. Imaging was performed with an 
EVOS XL Core Imaging System (Thermo Fisher Scientific). 
 
Treatment of mice bearing xenografts with CB5 
 All mice were obtained from were obtained from the Johns Hopkins University 
Sidney Kimmel Comprehensive Cancer Center Office of Research Services Animal 
Resources. 
 Toxicity of CB5 in mice: CB5 was dissolved at a concentration of 20 mg/mL into 
DMSO. CB5/DMSO was diluted into sterile PBS and sonicated in a water-bath type 
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sonicator for 15 minutes at 30°C to form a stable suspension. (Sonication was performed 
before injections each day). Concentrations used were 10, 20, 40 and 80 μL of 
CB5/DMSO per mL for the doses of 2, 4, 8, and 16 mg/kg/day, respectively. Two 8-week 
old female NOD/SCID mice were obtained from the Johns Hopkins University Sidney 
Kimmel Comprehensive Cancer Center Office of Research Services Animal Resource. 
Each mouse received increasing doses of CB5 via a 200 μL intraperitoneal injection once 
daily. They received 2 mg/kg for 2 days, 4 mg/kg for 2 days, 8 mg/kg for 6 days, and 16 
mg/kg for 2 days. Animals were observed for 30 minutes following each injection to 
determine any acute side effects of CB5.  
 Toxicity was also assessed using Kolliphor HS 15 (Millipore Sigma) as a vehicle. 
A 30% solution (w/v) was made of Kolliphor HS 15 in PBS. The solution was sterilized 
by filtration. CB5 was dissolved directly into the Kolliphor solution. Two 12-week old 
female NOD/SCID mice received the following doses of CB5 in a daily 200 μL injection: 
2, 4, 8, 16, 32, and 64 mg/kg. Each dose was given for two days, and the final 64 mg/kg 
dose was given for 5 days. Animals were observed for several minutes after injections to 
determine any acute side effects.  
U87 xenografts: WT U87 cells were harvested via trypsin and counted. 4,000,000 
cells in 50 μL sterile PBS were injected subcutaneously into both hind flanks of 6 8-week 
old female NOD/SCID mice. Tumors were allowed to grow and measured every 2-3 day 
using calipers. Tumor volume was approximated using the following formula: volume = 
(length x width
2
)/2. Once average tumor size was approximately 100 mm
3
, daily drug 
injection began. CB5 was dissolved at a concentration of 20 mg/mL into DMSO, and 
then 10 μL CB5/DMSO was diluted into 1 mL sterile PBS and sonicated in a water-bath 
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type sonicator for 15 minutes at 30°C to form a stable suspension. 2 mg/kg CB5 was 
given to 3 mice via intraperitoneal injection once daily. The other 3 mice received 
equivalent volume of DMSO in PBS (vehicle). Mice receiving vehicle were sacrificed on 
Day 22, when average tumor volume exceeded 1 cm
3
. Mice receiving CB5 were 
sacrificed on Day 25 when a large outlier tumor volume exceeded 1 cm
3
. Tumors were 
excised and weighed after sacrifice.  
Mayo 22 xenografts: Mayo 22 cells were derived from a primary glioblastoma 
and are maintained by serial passage as subcutaneous xenografts. To implant new 
xenograft tumors, 500 mg was measured out from the previous generation’s subcutaneous 
xenograft. This tumor section was finely chopped, suspended in 5 mL of sterile PBS, and 
passed 6 times through a 16-gauge needle using a 10 mL syringe. The suspension was 
centrifuged, aspirated, and resuspended in 2 mL of PBS. 100 μL of this suspension was 
implanted to form each new tumor. (The passage protocol was adapted from Carlson and 
Sarkaria, 2011). 
Mayo 22 cells were implanted by subcutaneous injection into both hind flanks of 
8-week old female NOD/SCID mice. CB5 was dissolved at a concentration of 20 mg/mL 
into DMSO, and then 40 μL CB5/DMSO was diluted into 1 mL sterile PBS and sonicated 
in a water-bath type sonicator for 15 minutes at 30°C to form a stable suspension. Drug 
injection began on Day 9, when average tumor was approximately 100 mm
3
. 8 mg/kg 
CB5 was given to half of the mice while the others received equivalent DMSO in PBS 
via intraperitoneal injection once daily. Mice were sacrificed on Day 23 once some tumor 
volumes exceeded 1 cm
3






Validation of ACSVL3-KO U87 cell line  
 ACSVL3 expression in WT and ACSVL3-KO U87 cells was assessed with both 




ACSVL3 preferentially activates stearic and behenic acid 
As a member of the very-long chain synthetase family, it was expected that 
ACSVL3 would activate long and very long chain fatty acids. To test its specificity, the 
thioesterification of radiolabeled fatty acids to their CoA derivatives was measured in 
vitro using pelleted WT and ACSVL3-KO U87 cells. The KO cells showed reduced 
conversion of all fatty acids tested: palmitic, stearic, behenic, and lignoceric (Figure 4). 
However, the reduction of conversion of stearic and behenic acid was more consistent 
and statistically significant than the other two. This implies that stearic and behenic acid 
are preferred substrates of ACSVL3. Because stearic acid is thioesterified to CoA at a 
Figure 3: Expression of ACSVL3 in WT 
and ACSVL3-KO U87 cells 
 
The expression of ACSVL3 in WT and 
ACSVL3-KO U87 cells was evaluated with 
immunofluorescence (A) and Western blot 




much higher rate than behenic acid, it was chosen for use in later experiments searching 
for ACSVL3 inhibitors. 
 
 
Figure 4: Total activation of long- and very-long chain fatty acids in WT and 
ACSVL3-KO U87 cells 
 
Protein from WT and ACSVL3-KO U87 cells were assayed for conversion of [1-
14
C]-
labeled fatty acids to their CoA derivatives. A total of 4 samples were assayed for each 
fatty acid.  C16:0/palmitic acid (A) and C18:0/stearic acid (B) are considered long-
chain fatty acids, and C22:0/behenic acid (C) and C24:0/lignoceric acid (D) are 
considered very long-chain fatty acids.  There was a slight decrease in the activation of 
C16:0 and C24:0 in protein from ACSVL3-KO U87 cells, but the difference was not 
statistically significant.  Activation of C18:0 and C22:0 was statistically decreased 
(p<0.001) in protein from ACSVL3-KO U87 cells. 
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ACSVL1 inhibitors also inhibit ACSVL3 
Several known inhibitors of ACSVL1 were screened for inhibition of ACSVL3. 
Inhibitors tested were the approved drugs triflupromazine, phenazopyridine, 
chlorpromazine, emodin, and perphenazine, and molecules from the ChemBridge 
Corporation compound library referred to as CB2, CB5, CB6, and CB16.2.The 
conversion of stearate to stearyl-CoA was again measured in WT and ACSVL3-KO U87 
cells. Either 80 μM of a known ACSVL1 inhibitor or the equivalent volume of DMSO 
(control) was added to the assay. Most of the inhibitors of ACSVL1 inhibited conversion 
of stearate to stearoyl-CoA in WT U87 cells (Figure 5). However, this assay measures the 
total activity of all acyl-CoA synthetases in the cell pellet, not just ACSVL3. For this 
reason, synthetase activity on WT and KO U87 cells was compared. Figure 5a shows the 
fraction of conversion in the presence of inhibitors compared to DMSO, while Figure 5b 
shows the difference in total conversion of stearate to stearyl CoA in the presence of the 
inhibitors. An inhibitor is likely somewhat specific if it lowers total conversion of stearate 
to stearyl-CoA more in WT than ACSVL3-KO cells by one of these two measures. All of 
the ACSVL1 inhibitors except CB6 and CB16.2 lowered total conversion of stearate by a 
larger margin in WT compared to ACSVL3-KO U87 cells. The following inhibitors 
showed a greater percent decrease in WT versus ACSVL3-KO U87 cells: 
phenazopyridine, chlorpromazine, emodin, CB2, CB5, and CB16.2. 
Since CB5 and CB16.2 were very inhibitory of conversion of stearate at 80 μM, 
assays were repeated with lower doses of these two molecules. Again, the difference in 
inhibition in WT and ACSVL3-KO U87 cells was compared (Figure 5c and d). The 
inhibitory effect of CB16.2 was greatly decreased at these lower concentrations. CB5 still 
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inhibited most ACS activity when added to the assay at 10 μM, but not when added at 1 
μM or 0.1 μM. As CB5 appears to be the most inhibitory molecule studied, it was 







Figure 5: Inhibition of C18:0 activation by ACSVL1 inhibitors in WT and 
ACSVL3-KO U87 cells 
 
80 µM of various ACSVL1 inhibitors was added to assays assessing the conversion of 
[1-
14
C]-labeled C18:0 to its CoA derivative in protein from both WT and ACSVL3-
KO U87 cells. For each drug or compound, the fraction of activity compared to assays 
containing DMSO (negative control) is shown (A). The total decrease in ACS activity, 
normalized to the DMSO control in each assay, is also shown (B). An inhibitor that is 
somewhat specific for ACSVL3 should exhibit either a higher fraction of activity in 
KO vs. WT, or a larger total difference in ACS activity in KO vs. WT. CB5 and 
CB16.2 were determined to be the most robust inhibitors and were added to ACS 
assays in smaller concentrations. Again, the fraction of activity (C) and the total 
decrease in ACS activity (D) are shown. 10 µM CB5 inhibited ACS activity robustly, 
10 µM CB16.2 inhibited ACS activity partially (but less robustly than CB5), and 
lower concentrations of both drugs did not inhibit ACS activity.  
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Characterization of a domain-swapped ACSVL1/3 hybrid 
To couple the ability to uptake the fluorescent fatty acid analog, C1-BODIPY-C12, 
with the enzymatic activity of ACSVL3, a hybrid was generated comprised of the 
regulatory, N-terminal domain of ACSVL1 and the enzymatic C-terminal domain of 
ACSVL3 (illustrated in Figure 6a). The construct was cloned into the plasmid pcDNA3 
and transfected into Cos-1 cells. ACSVL1 and ACSVL3 were also each cloned into 
pcDNA3, and these constructs, as well as the empty vector, were each expressed in Cos-1 
cells for comparison. 
Fluorescence microscopy and a quantitative, fluorescence-based plate-reader 
assay were used to compare the uptake of C1-BODIPY-C12 by Cos-1 cells expressing 
ACSVL1, ACSVL3, the hybrid ACSVL1/3, and the empty vector pcDNA3. By 
microscopy, cells expressing ACSVL3 and pcDNA3 do not uptake C1-BODIPY-C12 
while ACSVL1 and ACSVL1/3 both uptake C1-BODIPY-C12 at similar levels (Figure 
6b). By the plate-reader assay, cells expressing ACSVL3 and pcDNA3 again show 
similar, lower levels of C1-BODIPY-C12 uptake, while cells expressing ACSVL1 and 





Most ACSVL1 inhibitors also inhibit uptake of C1-BODIPY-C12 and the acyl-CoA 
synthetase activity of ACSVL1/3 
The same set of ACSVL1 inhibitors that were screened in the ACS activity assay 
were tested to see if they would inhibit uptake of C1-BODIPY-C12 in Cos-1 cells 
expressing ACSVL1/3. Each was added in multiple concentrations from 0.1 to 5 μM in 
duplicate wells in a 96-well plate. Many of the inhibitors showed a dose-dependent 
Figure 6: Characterization of the ACSVL1/3 hybrid enzyme 
 
A. The domain swapped hybrid is illustrated. Cos-1 cells were transfected with the 
empty vector (pcDNA3) or a plasmid containing ACSVL1, ACSVL3 or the hybrid 
ACSVL1/3. These cells were evaluated for their ability to uptake C1-BODIPY-C12 by 
quantification of fluorescence in a plate reader (B) or immunofluorescence (C). For 
quantification of fluorescence, triplicates of Cos-1 cells expressing each construct 
were evaluated. ACSVL1 and ACSVl1/3 both showed increased uptake of C1-
BODIPY-C12 compared to pcDNA 3 (p < 0.001), demonstrating that the domain swap 
conferred the ability to uptake C1-BODIPY-C12 to the catalytic domain of ACSVL3. 
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inhibition of C1-BODIPY-C12 uptake (Figure 7a). Again, the compounds CB5 and 
CB16.2 were found to be the most potent.  
CB5 and CB16.2 were added to acyl-CoA synthetase assays measuring the 
conversion of radiolabeled stearic acid to stearyl-CoA to asses if they would have a 
similar inhibitory effect on ACSVL1/3 as they did on ACSVL3. Both drugs were tested 
at concentrations of 10 μM and 1 μM. Pellets from Cos-1 cells overexpressing all 
constructs (ACSVL1, ACSVL3, ACSVL1/3, and pcDNA3) were assayed. While 10 μM 
and 1 μM CB16.2 as well as 1 μM CB5 had minor inhibitory effects, 10 μM CB5 
inhibited stearate conversion in all constructs (Figure 7b and 7c). (The inhibition seen in 
cells expressing pcDNA3 can be attributed to inhibition of long- and very long-chain 






Figure 7: Inhibition of ACSVL1/3 by ACSVL1 inhibitors 
 
A. Cos-1 cells expressing ACSVl1/3 were treated with various concentrations of 
ACSVl1 inhibitors, then assayed for the ability to uptake C1-BODIPY-C12. 
Fluorescence was quantified. Most drugs and compounds inhibited C1-BODIPY-C12 
uptake in a dose-dependent manner. B. CB5 and CB16.2 were added to assays 
assessing the conversion of [1-
14
C]-labeled C18:0 to its CoA derivative in protein 
from Cos-1 cells expressing ACSVL1, ACSVL3, ACSVL1/3, or the empty vector 
pcDNA3. The fraction of activity compared to a DMSO control is shown. 10 µM CB5 
inhibited Cos-1 cells containing each vector, including empty vector pcDNA3, most 




CB5 slows the growth rate of U87 cells in culture 
Due to its dramatic effects on acyl-CoA synthetase activity, the effects of CB5 on 
cells in culture were characterized. First, 10 μM CB5 was added to media of U87 cells in 
culture. This appeared to be toxic to the cells; many cells detached over the course of 
several days or gained a rounded, sick-looking morphology. Next 3 μM CB5 was added 
to U87 cells in culture, which were counted every 3 days. CB5 appeared to have no 
negative effects on cell adherence and mortality. However, it did significantly slow the 
growth rate of the U87s (Figure 8a). U87 cells grown in 3 μM CB5 grew slower than not 
only WT U87 cells treated with DMSO but also ACSVL3-KO U87 cells. 3 μM CB5 
appeared to be somewhat toxic to ACSVL3-KO cells, as the number of cells began to 
decrease slightly after 9 days of treatment. 
WT U87 cells were then treated for 12 days with varying concentrations of CB5. 
The cells were collected and counted. Growth was found to be inhibited by CB5 in a 
dose-dependent manner (Figure 8b). The usable range of CB5 is very narrow; 1 μM CB5 








CB5 changes the morphology of U87 cells in culture 
WT U87 cells treated with 3 μM CB5 grew larger and grew longer projections 
compared to U87 cells treated with DMSO over several days of treatment (Figure 9). 
This morphology is different from the morphology of ACSVL3-KO cells, which is also 
distinct from WT U87 morphology and is characterized by larger cells. The morphology 
induced by CB5 contributed to the hypothesis that CB5 may induce differentiation of WT 
U87 cells. 
Figure 8: Inhibition of U87 proliferation by CB5 
 
A. WT and ACSVL3-KO U87 cells were treated with either 3 µM CB5 or DMSO. 
5000 cells were seeded in 6-well plates on Day 0. Cells from triplicate wells were 
counted every 3 days for 15 days. CB5 dramatically decreased the growth rate of both 
cell lines. Notably, the rate of proliferation of CB5-treated WT U87 cells was lower 
than the rate of untreated ACSVL3-KO U87 cells. B. Various concentrations of CB5 
were given to WT U87 cells for 12 days, after which cells were counted. The 
therapeutic range of CB5 on U87 cells in vitro is narrow; 1 µM or less has no effect on 
proliferation rate, while 10 µM or more is toxic. 3 µM CB5, the dose used for other in 
vitro experiments using U87 cells, is near the lower point of inflection of the S-shaped 





When CB5 is removed from cells in culture, the growth rate reverts after several 
days 
WT U87 cells were treated for 9 days with CB5. Media containing CB5 was 
removed from half of the groups of cells and replaced with media containing equivalent 
DMSO. The growth rate of the U87s from which CB5 was removed continued to grow 
slowly for several days, but the rate eventually increased to an exponential rate (as seen 
in WT U87 cells treated with DMSO) around Day 21, or 12 days after CB5 was removed 
(Figure 10). 
Figure 9: Morphology of U87 cells treated with CB5 
 
WT U87 cells were treated with 3 µM CB5 for 12 days. CB5 treatment induced a 
unique morphology in U87 cells. The cells grew larger and grew long projections. The 
morphology of ACSVL3-KO U87 cells is shown for comparison. ACSVL3-KO cells 
also have a morphology distinct from WT U87 morphology, and it is also dissimilar to 





CB5 does not affect cell growth or morphology of human fibroblasts  
To test the effect of CB5 on a non-cancerous cell line, human fibroblasts in 
culture were treated with various concentrations of CB5 for 5 days. At all concentrations 
tested, CB5 did not appear to have an obvious effect on cell growth or morphology 





Figure 10: Reversion of growth rate in U87 treated with CB5 after drug removal  
 
WT U87 cells were treated with DMSO or 3 µM CB5 for 9 days, then CB5 was 
removed from half of the treated cells and replaced with DMSO. Cells were counted 
every 3 days. Several days after removal, U87 cells that had been previously treated 
with CB5 resumed the untreated growth rate.  A statistical difference was seen in 





CB5 decreases invasiveness of U87 cells as measured by the scratch-wound assay 
The scratch-wound assay was used to compare the invasiveness of WT U87 cells 
treated with 3 μM CB5 to WT and ACSVL3-KO U87 cells. For each condition, a layer of 
cells growing in culture was scratched, and the ability of the cells to close the scratch was 
assessed. After 48 hours, the scratch in the cells treated with CB5 remained visible, while 
the scratch in the DMSO-treated WT U87 cells had closed (Figure 12a). Quantification of 
the scratch size reveals that DMSO-treated WT U87 cells closed the scratch the quickest, 
followed by DMSO treated ACSVL3-KO U87s, and CB5-treated WT U87 cells closed 
the scratch the slowest (Figure 12b). While this assay does not demonstrate whether cell 
migration or cell division is a bigger factor in closing the scratch, it does suggest that 
CB5-treated U87 cells are less invasive than both WT and ACSVL3-KO U87 cells 
treated with DMSO. 
Figure 11: Treatment of human fibroblasts with CB5 
 
Human skin fibroblasts were treated with varying concentrations of CB5 and observed 
for 5 days. None of the concentrations tested, including 10 µM CB5, which was found 





CB5 decreases β-oxidation of long-chain fatty acids in U87 cells 
To determine whether CB5 affects the degradation of long- and very long-chain 
fatty acids, various radiolabeled fatty acids were given to WT U87 cells in culture. The 
U87 cells were treated with either 3 μM CB5 or DMSO for 1.5 hour prior to the 2 hour 
incubation with a fatty acid. Fatty acids tested were palmitic, stearic, oleic, behenic, and 
lignoceric acids. After incubation, water soluble products were extracted to assess the 
breakdown of the fatty acids.  
Figure 12: Scratch-wound assay of CB5-treated U87 cells 
 
The scratch-wound assay was used to assess invasion of WT U87 cells treated with 
either 3 µM CB5 or DMSO. ACSVL3-KO cells treated with DMSO were also 
compared. Quantification of the scratch sizes in each condition (A) and images of the 
scratches in CB5- and DMSO-treated U87 cells (B) are shown. In CB5-treated U87 
cells, the scratch closed more slowly than in either WT or ACSVL3-KO cells. Scratch 
sizes were quantified using ImageJ (Schindelin et al., 2015). 
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β-oxidation of palmitic, stearic, and oleic acids was reduced in the presence of 
CB5 (Figure 13). β-oxidation of behenic acid appeared to be only slightly reduced. The 
background was very high in the lignoceric acid assay, but β-oxidation again appeared to 
be reduced. Due to lower amounts of very-long chain fatty acids, and therefore lower 
utilization in WT cells, it is difficult to study β-oxidation of these fatty acids because of 




CB5 induces differentiation of U87 cells 
To determine whether CB5 induces differentiation of U87 cells, expression of the 
astrocyte-specific marker glial fibrillary acidic protein (GFAP) was assessed by 
immunofluorescence and western blot. CB5-treated cells showed higher levels of GFAP 
Figure 13: β-oxidation of long- and very long-chain fatty acids in U87 cells 
 
The conversion of [1-
14
C]-labeled fatty acids to their water soluble β-oxidation 
products over a 2 hr period was assayed in U87 cells treated with either 3 µM CB5 or 
DMSO.  Cells were treated with CB5 for approximate 1.5 hr prior to the addition of 
labeled fatty acids. CB5 decreased the rate of β-oxidation of each fatty acid, especially 
the long-chain fatty acids C16:0, C18:0, and C18:1. 
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in U87 cells treated for 9 days with 3 μM CB5 compared to cells treated with DMSO 
(Figure K). While RNAi knock-down of ACSVL3 led to an increase of GFAP in U87s 
(Sun et al., 2014), the ACSVL3-KO U87 line did not exhibit this phenotype by 
immunofluorescence.   
 
     
CB5 is well tolerated by mice 
CB16.2 was toxic to mice in doses larger than 2 mg/kg when given by 
intraperitoneal injection; mice became immobile for several minutes after dosing (C. 
DiRusso, University of Nebraska-Lincoln, personal communication). To avoid potential 
toxicity of CB5, initial treatments of mice bearing xenografts used the same 
concentration, 2 mg/kg, of CB5 injected once per day. CB5 was dissolved in DMSO, 
which was then diluted into PBS to form a stable suspension. CB5 seemed to be better 
tolerated that CB16.2. NOD/SCID mice were treated with 2 mg/kg/day for 2 days, then 4 
mg/kg/day for 2 days, 8 mg/kg/day for 6 days, and finally 16 mg/kg/day for 2 days. At no 
Figure 14: Expression of GFAP in U87 
cells 
 
Expression of the astrocyte-specific protein 
GFAP was evaluated in WT U87 cells 
treated with 3 µM CB5 or DMSO for 9 days 
and ACSVL3-KO U87 cells. GFAP, a 
marker of differentiation, was detected using 
immunofluorescence (A) and Western 
blotting (B). GFAP was much more 
abundant in CB5-treated U87 cells than 
either WT or ACSCL3-KO U87 cells.  
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point did the mice exhibit any obvious side effects, including the CNS side effects 
reported with larger doses of CB16.2. 
Next, NOD/SCID mice were treated with CB5 dissolved in Kolliphor HS 15, 
which allowed CB5 to go into solution rather than the suspension of DMSO/PBS. This 
vehicle was tried in case CB5 was more bioavailable in solution rather than suspension. 
NOD/SCID mice were treated with the following doses for 2 days each: 2, 4, 8, 16, and 
32 mg/kg. At all of these concentrations, CB5 was entirely dissolved in solution. Finally, 
the mice were treated for 5 days with the highest dose tested, 64mg/kg/day. This 
concentration did not go fully into solution but did form a stable solution. The mice did 
not exhibit obvious side effects from any doses. While the purpose of this study was to 
determine a toxic dose of CB5, no higher doses were given due to the limitations of 
getting CB5 into solution/suspension.  
 
CB5 slows tumor growth in mice bearing U87 xenograft tumors but not Mayo-22 
xenograft tumors 
NOD/SCID mice were injected subcutaneously on both hind flanks with U87 
cells to form xenograft tumors. Once the tumors had grown to an approximate average 
volume of 100 mm
3
, half of the mice began to receive a daily injection of CB5 
(2mg/kg/day) while the other half received equivalent DMSO. Tumors were measured 
every 2-3 days. After 7 days of treatment (15 days post-xenograft implantation), tumors 
in the mice treated with DMSO began to grow more rapidly than those treated with CB5 
(Figure 15a). After 12 days of treatment (20 days post-implantation), tumors in the mice 
treated with CB5 began, on average, to decrease in size. The tumor sizes exhibited by the 
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CB5-treated mice (except for one outlier, where z = 2.0 for final tumor weight) then 
stagnated. DMSO-treated mice were sacrificed on post-injection day 22 and CB5-treated 
mice on day 25. Despite this, harvested tumors from CB5-treated mice were on average 
much smaller than tumors from DMSO-treated mice (Figure 15b). Of the 6 total tumors 
from mice treated with CB5, one was an outlier; it grew at a similar rate to the tumors 
from the DMSO-treated mice. (The tumor on the mouse’s other flank responded similarly 
to the other tumors from CB5-treated mice.) 
 Next, another cohort of NOD/SCID mice were injected subcutaneously with 
Mayo 22 cells and allowed to grow to approximately 100 mm
3
. Half of the mice then 
began receiving daily injections of CB5, this time at a higher dose of 8 mg/kg while the 
other half received equivalent DMSO. Tumors were measured every 2-3 days. Tumor 
growth was very variable within both the group of mice receiving CB5 and the group 
receiving DMSO. Furthermore, there was no statistical difference in estimated tumor 







Figure 15: Treatment of mice bearing glioblastoma xenograft tumors with CB5 
 
A. Mice bearing subcutaneous xenograft tumors formed from U87 cells were treated 
with 2 mg/kg/day CB5 or equivalent DMSO beginning 8 days after tumor 
implantation. Tumor size was approximated every 2-3 days by measuring with 
calipers. Vehicle-treated mice were sacrificed 22 days after xenograft implantation, 
and CB5-treated mice were sacrificed 25 days after injection. Except for one outlier, 
the tumors on the CB5-treated mice grew slower and even decreased in volume over 
the course of treatment. Final tumor weight after sacrifice is shown (B) although 
animals were sacrificed on different days (n= 6 for each condition, p < 0.01 if outlier 
is excluded). C. Mice bearing tumors formed from Mayo-22 cells were treated with 8 
mg/kg/day CB5 beginning 9 days after tumor implantation. Approximate tumor size is 
shown. Mice were sacrificed 22 days after tumor implantation. There was no 
significant difference in approximate tumor size at any time point or final tumor 





There are two main reasons to find an ACSVL3 inhibitor. First, a good inhibitor 
can be used to help understand the biology of ACSVL3 and tumorigenesis, and second, 
an inhibitor could have therapeutic potential in patients suffering from glioma. These 
experiments have identified inhibitors of ACSVL3 activity, and the most robust one, 
CB5, shows potential for both purposes.  
A difficulty in finding inhibitors of acyl-CoA synthetases is that these enzymes 
overlap in function. U87 cells contain other long-chain and very-long chain ACS family 
members that likely activate stearic acid to stearyl-CoA, making it difficult to create a 
screen for inhibition of ACSVL3 activity alone. We have combated that by comparing 
ACS activity in WT U87 cellular protein to ACSVL3-KO U87 protein. If the inhibitors 
screened are somewhat specific for ACSVL3, they are expected to inhibit stearic acid 
activation more robustly in WT than in ACSVL3-KO U87 cellular protein. An ideal 
inhibitor (one that displayed no cross-reactivity with other ACS family members) would 
inhibit stearic acid activation in WT U87 cellular protein and would not affect activation 
in ACSVL3-KO protein. However, due to the high homology of the enzymatic regions of 
ACS enzymes, it is unlikely that a completely specific inhibitor will be found.  
    However, for therapeutic uses of identified inhibitors, specificity is not critical. The 
most important consideration is that the inhibitor combats cancerous phenotypes. For 
studying the biochemistry of ACSVL3 in glioma, a highly specific inhibitor would be 
most ideal. The ACSVL3-KO line has been very useful in characterizing the role that 
ACSVL3 plays in lipid metabolism in glioma, and halting ACSVL3 activity with an 
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inhibitor would in theory produce the same phenotypes exhibited in the KO line. 
However, my experiments demonstrate that this is not always the case. For example, 
CB5-treated U87 cells show an increase in GFAP over DMSO-treated U87 cells by 
immunofluorescence, while ACSVL3-KO cells did not show an increase. Many of the 
differences in ACSVL3-KO U87 cells versus CB5-treated U87 cells can be attributed to 
compensatory changes that arise in the KO line to combat the loss of ACSVL3. We know 
by proteomics that many proteins are upregulated or downregulated in the ACSVL3-KO 
line compared to WT U87s (Kolar, 2016), and while some of these changes are likely 
induced by CB5, using an inhibitor allows us to study the mechanism of ACSVL3 in 
glioma without worrying about as many compensatory changes that arise over time. 
    The small molecule CB5 was identified as a robust inhibitor of ACSVL3. We used two 
metrics to characterize potential inhibitors. First was the inhibition of the 
thioesterification of stearic acid to stearoyl-CoA. Stearic acid was chosen above other 
long- and very long-chain fatty acids because it is activated preferentially by ACSVL3 at 
a relatively high rate. The second metric was the inhibition of uptake of C1-BODIPY-C12 
in Cos-1 cells expressing the chimeric protein ACSVL1/3. By both metrics, CB5 was the 
most robust inhibitor of ACSVL3 activity. Therefore, it was chosen for further study to 
determine if it had therapeutic potential in glioma cells. 
    As a robust inhibitor of ACSVL1 (Sandoval et al., 2010), it was expected that CB16.2 
would be a good inhibitor of CB5 as well. However, results were mixed. CB16.2 
inhibited uptake of BODIPY in Cos-1 cells expressing ACSVL1/3 approximately as well 
as CB5. At a concentration of 80 μM, CB16.2 inhibited conversion of stearate to stearyl-
CoA less robustly than CB5 but better than any other inhibitor, but at 10 μM, CB5 
55 
 
significantly outperformed CB16.2. These inconsistencies may be due to the face that 
CB16.2 appeared to be less soluble than the other inhibitors, including CB5, in the 
solvents used. It seemed more likely to precipitate out of DMSO, and when the stock 
DMSO solution was added to the aqueous assays, it appeared to only go into suspension, 
which may or may not have been stable. CB16.2 may have been a better inhibitor by our 
metrics if it was solubilized in a different solvent.  
The chimera ACSVL1/3 was created to couple the ability to uptake C1-BODIPY-
C12 to the enzymatic activity of ACSVL3. Here a fluorescence-based assay was used to 
compare several potential ACSVL3 inhibitors at multiple concentrations at once. This 
setup will also be used to screen chemical libraries to find other inhibitors of ACSVL3. A 
library of approved drugs and natural products and the ChemBridge CNS-Set library will 
be screened for reduction of C1-BODIPY-C12 uptake by measuring intracellular 
fluorescence using a plate reader. Positive hits will be defined as drugs or compounds 
that lower total fluorescence by at least 3 standard deviations from the  mean of the 
control (no drug added) signal. A secondary screen will be performed to rule out 
decreases in fluorescence due to C1-BODIPY-C12 signal quenching, toxicity, or cellular 
membrane disruption. Identified drugs and compounds will be tested for inhibition of 
ACSVL3 synthetase activity in stably transfected COS-1 cells and U87 cells, with the 
ultimate goal to find multiple highly specific ACSVL3 inhibitors.  
The effects of CB5 treatment of U87 cells in culture support its potential as an 
anti-tumorigenic drug. First and foremost, CB5 treatment greatly slowed the rate of 
proliferation of WT U87 cells. Since rapid, under-regulated cellular proliferation is a 
hallmark of tumorigenesis, this was an encouraging finding. Furthermore, treatment with 
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CB5 significantly decreased the rate at which a scratch-wound healed, a common 
measurement of invasiveness.  
Toxicity was a concern since CB5 treatment led to some cellular death after 
several days in the ACSVL3-KO U87 cell line. However, treatment at high 
concentrations had no obvious effect on human fibroblasts, a non-cancerous cell line. 
This suggested that the drug may target tumor cells without affecting healthy cells, which 
is ideal for cancer therapeutic agents.  
Interestingly, CB5 had a narrow range of effectiveness. 1 μM CB5 had no effect 
on cell proliferation compared to DMSO, while 10 μM was toxic to  WT U87 cells. The 
effect of CB5 on proliferation was found to form an S-curve when cell number was 
plotted against CB5 concentration. The concentration 3 μM, which was used for most of 
the experiments performed on U87 cells in culture, was found to be at the lower point of 
inflection on this S-curve. This suggests that it may be an ideal does to use on cells in 
culture, balancing toxicity with effectiveness.  
Another effect of CB5 on U87 cells was an altered morphology. The large size 
and long projections induced by CB5 caused us to question whether CB5 was inducing 
differentiation in these cells. Increased GFAP in CB5-treated U87 cells as seen by both 
immunofluorescence and western blotting compared to DMSO-treated cells supported 
this hypothesis.  
If WT U87 cells that were previously treated with 3 μM CB5 are switched to 
DMSO treatment, the rate of cell growth eventually, after several days, reverts to the 
growth rate exhibited by U87 cells that were never treated with CB5. This raised the 
question of how this occurs, given that CB5 seems to induce differentiation of U87 cells. 
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A hypothesis is that this increased proliferation stems from a smaller, sub-population of 
CB5-treated cells, explaining why it takes several days to revert to the untreated rate. 
After several days of treatment with CB5, there were a few WT U87 cells that did not 
have the altered morphology induced by CB5, and when GFAP expression was evaluated 
via immunofluorescence, occasional cells were found that exhibited less GFAP. This 
hypothesis could also explain the outlier xenograft U87 tumor that did not respond to 
CB5 treatment. Future experiments will aim to characterize this heterogeneity in treated 
cells.  
The rate of β-oxidation of long-chain fatty acids decreased in WT U87 cells 
treated with CB5. While many of the changes exhibited by CB5-treated U87 cells appear 
over time, such as the altered morphology and expression of differentiation markers, this 
was an acute change, as cells were treated for only 1.5 hour prior to the assay. This makes 
sense, since fatty acids must be converted to acyl-CoA prior to β-oxidation. Because 
rapidly proliferating tumor cells need to generate a lot of energy, impairing β-oxidation 
may be one of the ways that CB5 slows proliferation of U87 cells.  
CB5 was well tolerated by mice and did not appear to cause any side effects at the 
IP doses tested, up to 16mg/kg/day in DMSO/PBS and 64 mg/kg/day in 30% Kolliphor 
HS-15. CB5 reduced the rate of growth of U87-based subcutaneous xenograft tumors 
treated with 2 mg/kg/day of CB5 but not in Mayo 22-based xenografts treated with 8 
mg/kg/day. The different responses could be explained by physiological differences 
between the two types of tumors, such as vascularization. Another possibility is that CB5 
is inhibiting tumor growth in U87 xenografts not by inhibition of ACSVL3 but by 
targeting another pathway. CB5 is also a known inhibitor of ADP-ribosylation factor 6 
58 
 
(Arf6), a GTP-binding protein that regulates endocytic recycling and cytoskeleton 
remodeling (World Patent No. 2015183989). It is possible that CB5 could be inhibiting 
Arf6 in U87-based xenografts but not in Mayo 22-based xenografts. Future directions 
include evaluating the level of Arf6 in both U87 and Mayo 22 cells.  
Another concern with CB5 treatment is the short half-life of the drug. CB5 has a 
half-life of 151.7 minutes in blood when given intravenously (C. DiRusso, University of 
Nebraska-Lincoln, personal communication). While IP injection likely leads to a longer 
half-life, better results may be achieved with multiple injections per day or a 
continuously-injecting, implanted micro-pump. Using a vehicle such as Kolliphor HS-15 
(Millipore Sigma), which was used to characterize CB16.2 in mice, may affect the 
potency of the drug as well. Future experiments will test different delivery systems and 
higher concentrations of CB5 on Mayo 22-based xenografts.  
It is not yet known if CB5 will cross the blood-brain barrier, which would be ideal 
for treating gliomas. A future experiment will be to treat mice bearing intracranial 
xenografts with CB5 and determine if the drug is still effective at reducing tumor growth 
rate. 










Glycosyl phosphatidylinositol (GPI) anchors are lipid-based, post-translational 
modifications found in all eukaryotes that attach proteins to the cell surface. The core 
structure of a GPI anchor is phosphatidyl inositol (PI) that is partially inserted into the 
cell’s plasma membrane, a central glycan core, and an ethanolamine phosphate sourced 
from phosphatidylethanolamine (PE) that is amide-bonded to the C-terminus of the GPI-
anchored protein. In mammals,the PI moiety is a 1-alkyl 2-acyl phosphatidylinositol 
(Kinoshita and Takeda, 1994). The glycan core is comprised of one non-acetylated 
glucosamine and three mannose residues, and often there are glycan-based or side-
branches or an additional linked PE moiety (Figure 16). GPI anchors are synthesized in 
the endoplasmic reticulum in a stepwise series of reactions catalyzed by GPI-GlcNAc 
transferase (GPI-T), then the anchor is transferred to the C-terminus of a protein by GPI 
transamidase (Kinoshita and Fujita, 2016). GPI anchors can be cleaved by 
phosphoinositide phospholipase C (PI-PLC), which hydrolyzes the phosphodiester bond 
of the PI molecule. After cleavage, the remaining GPI anchor has an exposed inositol 
cyclic-1,2-phosphate, referred to as the cross-reacting determinant (CRD). The CRD can 
be detected with an antibody, making the cleavage of GPI anchors and the subsequent 
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We have demonstrated that knockdown of ACSVL3 in U87 cells leads to 
decreased PI and PE synthesis in WT U87 cells (unpublished data). Since these are the 
two lipids required for GPI anchor synthesis, we hypothesized that ACSVL3-KO U87 
cells would have lower levels of GPI-anchored proteins than WT U87 cells. Also 
supporting this hypothesis is the known role of GPI-anchored proteins in a range of 
cancers. Several subunits of GPI-T have been identified as oncogenes in various forms of 
Figure 16: Diagram of a human GPI-anchored protein 
 
A human GPI anchor is comprised of a 1-alkyl 2-acyl phosphatidylinositol moiety 
(PI), a non-acetylated glucosamine (GlcN), three mannose residues (Man), and an 
ethanolamine phosphate group that is amide-bonded to the C-terminus of the protein. 
The alkyl and acyl chains of the PI moiety are inserted into the plasma membrane, 
anchoring the protein. The saccharides can be modified with side chains. The site of 
cleavage by the enzyme PI-PLC, which releases the protein from the membrane and 
exposes the CRD, is indicated. 
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cancer, and many GPI-anchored proteins themselves are oncogenes or biomarkers of 
cancer (Gamage and Hendrickson, 2013).  
We selected several common GPI-anchored proteins and tested for their 
expression in WT and ACSVL3-KO U87 cells: acetylcholinesterase (AchE), decay 
accelerating factor (DAF), 5'-Nucleotidase Ecto (NT5E), Alkaline Phosphatase, tissue 
nonspecific isoform (ALPL), and Thy-1 Cell Surface Antigen (Thy1). AchE aids cell 
proliferation, and increased AchE activity has been found in brain tumors (Barbosa et al., 
2001). NT5E is overexpressed in glioma, where it aids cell adhesion and interaction with 
the extracellular matrix (Cappellari et al., 2012). DAF, a complement system regulator, 
has variable expression in primary and immortalized glioma cells (Mäenpää et al., 
1996).  Thy-1 is often expressed in neural and glial cell lines as well as in neuroma tissue 
(Kenshead et al., 1982). In gliomas, Thy-1 has been identified as a good biomarker for 
cancer stem cells (Parry and Engh, 2012). ALPL is a stem cell marker, and its presence in 
gliomas is associated with necrosis and poor patient outcomes (Iwadate et al., 2016).  
In this study, we use PCR to assess expression levels of GPI-anchored proteins in 
WT and ACSVL3-KO U87 cells. PI-PLC was isolated from E. coli, assayed for activity, 
and used to cleave GPI anchors in both cell lines, which can then be detected by their 
CRDs. We demonstrate that while several GPI-anchored proteins are found in U87 cells, 
levels of GPI-anchored proteins do not vary significantly between WT and ACSVL3-KO 
U87 cells. Thus, GPI-anchored proteins likely do not contribute to the tumorigenic 





Materials and methods 
 
PCR 
RNA was extracted from WT and ACSVL3-KO cells using TRIzol reagent 
(Thermo Fisher Scientific) and concentration was measured with a NanoDrop ND-1000 
spectrophotometer. 3 μg of RNA per sample was used to synthesize cDNA using the 
SuperScript III Reverse Transcriptase kit (Thermo Fisher Scientific).  
Conventional PCR: Conventional PCR reactions were performed using the 
Invitrogen Platinum Taq DNA Polymerase kit (Thermo Fisher). The temperatures and 
times used in the reactions were as follows: initial melting temperature of 95°C for 45 
seconds, melting temperature of 95°C for 23 seconds for each cycle, annealing 
temperature of 55°C for 15 seconds for each cycle, extension temperature of 68°C of 15 
seconds for each cycle, and final temperature of 68°C for 5 minutes. Forty cycles were 





Table 2: Primer sequences used to detect transcripts encoding for common  
GPI-anchored proteins 
 
Gene Forward primer sequence Reverse primer sequence 
Acetylcholinesterase (AchE) GGGGCTCAGCAGTACGTTAG TTCCAGTGCACCATGTAGGA 
Decay Accelerating Factor 
(DAF) 
TTCACCATGATTGGAGAGCA CTGAACTGTTGGTGGGACCT 
5'-Nucleotidase Ecto (NT5E) GCCGCTTTAGAGAATGCAAC CAGGTTTTCGGGAAAGATCA 
Alkaline Phosphatase, tissue 
nonspecific isoform (ALPL) 
CCTCCTCGGAAGACACTCTG GCAGTGAAGGGCTTCTTGTC 







Quantitative PCR (qPCR): Each qPCR reaction was comprised of 7.5 μL of 
SYBR Green Master Mix (Thermo Fisher Scientific), 1 μL each of forward and reverse 
primers, 5 μL cDNA, and 0.5 μL H2O. The reactions were carried out in a Bio-Rad 
CFX96 Real Time PCR Detection System. The same temperatures, times, and primers 
used for conventional PCR were used again for qPCR, and 35 cycles were performed. 
GAPDH was used as a control to normalize results. 
 
Purification of PI-PLC 
Induction of PI-PLC expression in E. coli: LB plates bearing streaks of E. coli 
expressing an inducible plasmid containing PI-PLC were obtained from Dr. Charles 
Barlowe (Geisel School of Medicine at Dartmouth). 5 mL cultures were grown in LB at 
37°C for 8 hours, then 40 mL cultures were grown overnight.  
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Bacteria from the overnight culture were added to a new 200 mL culture so that 
the optical density at 600 nm (OD600) was 0.125. This new culture was grown at 37°C to 
an OD600 of 0.5, then 1 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) was added 
to induce PI-PLC expression. (A small sample was removed prior to the addition of IPTG 
as an uninduced control.) The culture was grown in the presence of IPTG at 37°C for 3 
hrs. The culture was centrifuged at 7969g for 30 min. Media was decanted from the 
bacterial pellet, and the pellet was frozen at -80°C overnight.  
Bacterial Lysis: The pellet was thawed on ice and suspended in 3X its weight in a 
lysis buffer (50 mM Tris pH 8.0, 25 mM NaCl, 2 mM EDTA, and 0.1% Triton X-100). 1 
mg/mL of lysozyme (dissolved into 10 mM Tris-Cl pH 8.0 at 10 mg/mL) and protease 
inhibitor (Calbiochem) were added to the suspension. The suspension was then incubated 
at 37°C in a water bath shaker for 30 minutes. The suspension was frozen at -80°C, 
thawed, and then incubated again at 37°C in a water bath shaker for 15 minutes. Next, 
DNAse I was added at a concentration of 0.1 mg/mL (dissolved at 1 mg/mL into 10 mM 
Tris-CL pH 7.5 containing 150 mM NaCl and 1 mM MgCl2), then 0.1 M MgCl2 was 
added. The suspension was incubated at 37°C in a water bath shaker until the suspension 
was no longer viscous from DNA, approximately 15-30 min. The suspension was 
centrifuged at 12,000g for 15 min at 4°C, then decanted. The supernatant (referred to as 
“Supernatant 1”) was saved, and the pellet was resuspended into a stronger lysis buffer 
(50 mM Tris pH 8.0, 25 mM NaCl, 10 mM EDTA, and 0.5% Triton X-100). This 
suspension was incubated at 37°C in a water bath shaker for 15 minutes, centrifuged at 
12,000g for 15 min at 4°C, and again decanted. The pellet and the supernatant (referred to 
as “Supernatant 2”) were saved. Both supernatants and the pellet were loaded on a 10% 
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acrylamide gel, and proteins were separated by SDS-PAGE. The gel was stained with 
Coomassie Blue to determine which fraction contained the most PI-PLC. 
PI-PLC Purification: The purification procedure was adapted from Baldassare et 
al. (1989). All steps were performed at 4°C. A 1-cm diameter column was filled with 3.5 
cm Q Sepharose Fast Flow resin (GE Healthcare Life Sciences). The column was 
equilibrated with with 20 mM Tris pH 8.0. Since most PI-PLC was located in 
Supernatant 1, this supernatant was added to the column next. The column was then 
washed twice with 5 mL 20 mM Tris pH 8.0. A gradient salt buffer was used to elute PI-
PLC from the column. The buffer was 20 mM Tris pH 8.0 containing from 0 to 0.35 M 
NaCl. The total gradient elution volume was 50 mL, and ~2 mL fractions were collected. 
A sample from each fraction was loaded on a 10% acrylamide gel, and proteins were 
separated by SDS-PAGE to determine which fractions were enriched in PI-PLC. These 
fractions were pooled and concentrated using an Amicon Ultra 15 mL Centrifugal Filter 
Device (10 kDa MWCO; Millipore Sigma). To stabilize the enzyme, the final 
concentrated product was stored in 50% glycerol and 1 mM EDTA. 
 
PI-PLC activity assay 
To assess the activity of the purified PI-PLC, the activity of acetylcholinesterase 
released from erythrocyte membranes by PI-PLC was measured. This protocol was 
adapted from Ellman et al. (1961). 
Erythrocyte membrane preparation: This preparation protocol was adapted from 
Hanahan and Ekholm (1974). Expired packed red blood cells (American Red Cross) were 
obtained. The cells were thawed and diluted 50% into 0.172 M Tris pH 7.5 for a total 
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volume of approximately 1 mL. The suspension was mixed for 1 min. 6 mL of 11 mM 
Tris pH 7.5 was added 1 mL at a time while vortexing. The suspension was then left on 
ice for 5 min. The suspension was centrifuged at 20,000g for 40 min at 4°C. The 
supernatant was decanted, and the pellet was resuspended in 6 mL of 11 mM Tris pH 7.5. 
The entire wash process (suspension in 11 mM Tris pH 7.5, resting on ice, centrifugation, 
and decanting) was repeated 3 times for a total of 4 washes. After the final decantation, 
the pellet contained a hard red lower pellet (a clot) and a looser, light colored upper pellet 
(the membranes). 2 mL of 11 mM Tris pH 7.5 was added gently to resuspend the 
membranes but not the clot. The membrane preparation was stored at 4°C. 
Modified Ellman assay: For assays without prior PI-PLC treatment, the 
membrane preparation was diluted (3, 30, or 300 times) into phosphate buffer pH 8.0. 1 
mL was added to a 1 mL cuvette.  
For assays following PI-PLC treatment, the membrane preparation was diluted 30 
times into phosphate buffer pH 8.0. 33 μL of Supernatant 1 from the induction of PI-PLC 
expression, or 33 μL from a fraction from the Q sepharose column that had a high amount 
of purified PI-PLC, was mixed into the diluted membrane preparation. This suspension 
was placed on a shaker at 37°C for 2 hours. An Ultrafree-MC 0.45 μm filter unit 
(Millipore Sigma) was used to remove membranes from the suspension, and the 
remaining solution was transferred to a 1 mL cuvette.  
For all assays, 8.33 μL of 0.01 M 5,5'-dithio-bis-(2-nitrobenzoic acid) (DNTB) in 
phosphate buffer pH 7.0 was mixed into the cuvette. The spectrophotometer (Thermo 
Scientific Spectronic Genesys 5) was set to 412 nM and adjusted to zero. 6.66 μL of 
0.075 M acetylthiocholine iodide was mixed into the cuvette. Absorbance was recorded 
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every 10 seconds. Relative rates of AchE activity were determined by calculating the 
ratios of the slopes exhibited by the total absorbance plotted against time. 
 
GPI anchor digestion by PI-PLC 
This method was adapted from the protocol of Englund (1988). WT and 
ACSVL3-KO U87 cells were cultured as described in Chapter 1. Cells were collected by 
aspirating and rinsing culture plates, then adding PBS without calcium and magnesium 
and allowing cells to detach. Cells were pelleted and washed twice with PBS containing a 
protease inhibitor cocktail (Calbiochem). Protein concentration was determined via the 
Pierce 660 nm Protein Assay. Equal amounts of protein were loaded on a 10% 
acrylamide gel and separated by SDS-PAGE, and proteins were transferred from the gel 
to PVDF as described in Chapter 1. The membranes were incubated at 37°C in buffer 
containing 10 mM Tris pH 7.3, 150 mM NaCl, 2% Triton X-100, protease inhibitors, and 
purified PI-PLC. (10-, 50-, and 500-fold dilutions of PI-PLC were all performed.) A 
replicate membrane was incubated in buffer without PI-PLC as a negative control.  
After PI-PLC digestion, immunoblotting was performed as described in Chapter 
1. The primary antibody used was α-CRD (3 μL antibody solution per 1 mL milk 
solution) and the secondary was goat α-rabbit IgG-HRP (1:8000 dilution in milk solution; 









WT and ACSVL3-KO U87 cells express several GPI-anchored proteins commonly 
found in cancer cells 
As shown by conventional PCR, both WT and ACSVL3-KO U87 cells express 
mRNA for all five commonly GPI-anchored proteins that were tested (Figure 17a). While 
this is a diagnostic and not a quantitative PCR, the difference in brightness of some bands 
between WT and ACSVL3-KO warranted qPCR to compare expression levels. qPCR 
showed similar mRNA expression of all genes except for ALPL in WT and ACSVL3-KO 
U87 cells (Figure 17b). ALPL mRNA expression in ASCVL3-KO cells was about 17% 







Characterization of PI-PLC purification 
Figure 18a shows the results of the induction of PI-PLC in transformed E. coli. 
The most prominent band in the IPTG-induced total protein lane is approximately the 
expected size of PI-PLC (29 kDa) and thus is most likely induced PI-PLC. When the 
Figure 17: Expression of GPI-anchored proteins in WT and ACSVL3-KO U87 
cells 
 
A. PCR was performed using cDNA derived from mRNA extracted from WT and 
ACSVL3-KO U87 cells. Transcripts of GPI-anchored proteins commonly found in 
cancer were detected in both cell lines. B. Expression levels of mRNA transcripts of 
GPI-anchored proteins were compared between WT and ACSVL3-KO U87 cells. 
Levels were determined to be the same in all proteins except ALPL. Expression of 
ALPL transcripts in ACSVL3-KO U87 cells was approximately 17% of expression in 
WT U87 cells (n = 3 for each cell line, p < 0.01). 
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bacteria were lysed to release the expressed protein, PI-PLC was located in Supernatant 
1. Therefore, Supernatant 1 was purified using anion-exchange column chromatography. 
Bound protein was eluted with a salt gradient.  
Figure 18b shows the input and output of the column. The first wash has a large 
band at the expected size for PI-PLC, meaning the column may have been overloaded 
and not able to trap all of the PI-PLC. However, it appears that significant PI-PLC was 
retained by the column, since it eluted later in several of the collected fractions. Some PI-
PLC was visible via Coomassie Blue staining in fractions 5-16. The fractions with the 






Purified PI-PLC is enzymatically active 
In order to determine if the purified PI-PLC is enzymatically active, release of the 
abundant GPI-anchored protein acetylcholinesterase (AchE) from erythrocyte membranes 
was measured. The rationale is that PI-PLC purified from E. coli will release AchE from 
erythrocyte membranes, and then after the membranes are removed a modified Ellman 
assay can be performed to determine how much AchE was released, and thus how active 
Figure 18: Expression and purification of PI-PLC from E. coli 
 
A. E. coli expressing an inducible plasmid containing PI-PLC were grown in LB 
medium. PI-PLC expression was induced in one of the cultures with IPTG. Bacteria 
were lysed, and proteins were separated with SDS-PAGE and stained with Coomassie 
Blue. Induction of PI-PLC expression was successful. PI-PLC was found mainly in 
Supernatant 1 of the lysis procedure. B. PI-PLC was purified from Supernatant 1 using 
anion-exchange chromatography. Samples from the input, flow through, column 
washes, and collected fractions are shown. Proteins were again separated with SDS-
PAGE and stained with Coomassie Blue. Although some PI-PLC was lost during the 
column wash, much of it bound to the column and eluted in fractions 9-14.  
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the PI-PLC is. The Ellman assay measures AchE activity by measuring the conversion of 
one of its substrates, acetylthiocholine, to thiocholine (Ellman et al., 1961). Thiocholine 
reacts with DTNB in the assay to produce a yellow color that absorbs at 412 nm.  
Erythrocyte membranes were prepared from frozen, centrifuged red blood cells. 
To determine the relative activity of AchE found on the blood cell membranes, varying 
amounts of membranes were added to Ellman assays (Figure 19a). A 3-fold dilution of 
the membrane preparation caused the increase in absorbance to level out quickly, 
indicating that the acetylthiocholine had all been quickly converted; this revealed the 
upper limit and thus the useful range of the Ellman assay. 30-fold and 300-fold dilutions 
of the membrane preparation in the Ellman assay provided the desired linear increase in 
absorbances. However, the 300-fold dilution provided a very slow increase, so the 30-
fold dilution was selected to use in the modified Ellman assays coupled to PI-PLC 
activity.  
Membrane dilutions were incubated with solutions that contain PI-PLC: 
Supernatant 1 from the E. coli lysis, Wash 1 from the purification column, and Fraction 
13 from the purification column. Each of these was determined by Coomassie staining to 
have a high level of PI-PLC. Supernatant 1 and Wash 1 appeared to have more total PI-
PLC, but Fraction 13 was more purified. After the membrane dilutions were incubated in 
the solutions containing PI-PLC, the membranes were filtered out of solution so that only 
AchE that had been cleaved off of the membranes remained. Next, acetylthiocholine and 
DTNB were added to the solutions, and absorbance was recorded. An Ellman assay 
containing the same amount of membranes was performed as a positive control of the 
maximum expected AchE activity. Of the solutions containing PI-PLC, Fraction 13 
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cleaved the most GPI anchors as determined by AchE activity (Figure 19b). However, all 
solutions exhibited AchE activity and are therefore inferred to have PI-PLC activity. 
Figure 19c compares relative rates of AchE activity between the solutions. 
Figure 19: Assessment of purified PI-PLC activity using the Ellman assay 
 
A. Erythrocyte membranes were used as a source of AchE in Ellman assays, which 
measure the conversion of acetylthiocholine to thiocholine by AchE. Three different 
dilutions of an erythrocyte membrane preparation were compared in order to 
determine the ideal amount to use in the modified Ellman assays coupled to PI-PLC 
digestion. A 3-fold dilution quickly converted all the acetylthiocholine and revealed 
the upper limit of the Ellman assay. 30- and 300-fold dilutions provided the desired 
linear increase in absorbance, but the 300-fold dilution provided a very slow increase 
in absorbance. Thus, modified Ellman assays coupled to PI-PLC digestion used a 30-
fold dilution of erythrocyte membranes. B. Modified Ellman assays were performed 
by using PI-PLC to cleave AchE from erythrocyte membranes, then removing 
membranes by filtration and using released AchE in an Ellman assay. Erythrocyte 
membranes were incubated with solutions from the purification process that were 
shown to contain PI-PLC by Coomassie staining: Supernatant 1 from the lysis process, 
Wash 1 of the anion-exchange column, and Fraction 13 from the column. Membranes 
were removed by filtration, and then aliquots from these solutions were added to 
Ellman assays. The slopes of the increases in absorbance represent the rate of 
conversion of acetylthiocholine, which is determined by the amount of AchE in the 
assay. In turn, the amount of AchE in the assay is determined by the amount cleaved 
by PI-PLC during the incubation with erythrocyte membranes. Therefore, the slopes of 
the increase in absorbance in the modified Ellman assay (shown in C) represent 
relative PI-PLC activity of the solutions incubated with erythrocyte membranes. 
Maximum activity was determined by including a traditional Ellman assay using the 
same amount of erythrocyte membranes, thus providing the maximum available 







WT and ACSVL3-KO U87 cells have similar levels of proteins with GPI anchors 
Total cellular protein from WT and ACSVL3-KO U87 cells was collected. 
Instead of collecting with trypsin, which could prematurely digest GPI-anchored proteins, 
cells were harvested by treating them with PBS containing no calcium or magnesium. 
WIthout these ions, the cells detached from the cell culture dishes while remaining intact. 
Total cellular proteins were separated by SDS-PAGE and were then transferred to PVDF 
membrane. PVDF membranes were incubated in purified PI-PLC. Following incubation, 
immunoblotting was performed with α-CRD primary antibody in order to detect cleaved 
GPI anchors. Several dilutions of PI-PLC were tested since the specific activity of the 
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purified, concentrated PI-PLC was unknown. A 1:50 dilution of PI-PLC was determined 
to be ideal, as incubation in this dilution resulted in several clear bands representing GPI-
anchored proteins without excessive noise (Figure 20a). When several samples of WT 
and ACSVL3-KO U87 protein were ran simultaneously, there were no apparent 
differences between band patterns or intensities in the final Western blot (Figure 20b). 
Therefore, there do not appear to be differences in the amount of GPI-anchored proteins 
between WT and ACSVL3-KO U87 cells.  
Ellman assays were also attempted using lysed WT U87 cells rather than 
erythrocyte membranes. Since U87 cells also express AchE, it was thought that they 
would also provide an increase in absorbance due to the production of thiocholine in an 
Ellman assay. The relative rates of the increases in absorbance could be used to compare 
GPI-anchored AchE levels between WT and ACSVL3-KO U87 cells. However, no 










Figure 20: Detection of GPI-anchored proteins in WT and ACSVL3-KO U87 
cells 
 
A. Proteins from WT and ACSVL3-KO U87 cells were collected, separated by SDS-
page, and transferred to PVDF. PVDF membranes were incubated in various dilutions 
of purified PI-PLC to cleave GPI anchors from proteins, revealing the CRD. CRDs 
were detected using Western blotting. A 1:50 dilution of PI-PLC was chosen to use in 
future on-membrane digestions. B.CRDs from proteins from triplicate WT and 
ACSVL3-KO cell samples were detected using Western blotting. No differences were 
seen between CRDs of WT and ACSVL3-KO U87 cells, indicating that there are 





U87 cells express several GPI-anchored proteins commonly found in cancer cells. 
Since GPI anchors are synthesized from the phospholipids PI and PE, and both of these 
are synthesized at a lower rate in ACSVL3-KO U87 cells compared to WT U87 cells, we 
hypothesized that GPI anchors would also be synthesized at a lower rate in ACSVL3-KO 
compared to WT U87 cells.  
Expression of several GPI-anchored proteins was evaluated by using qPCR to 
compare levels of mRNA. For most of the proteins, mRNA levels were similar between 
WT and ACSVL3-KO U87 cells. It was important to compare mRNA expression for two 
reasons: first, to  determine if GPI anchors were likely to be found in U87 cells, and 
second, to ensure that differences in GPI anchor levels between WT and ACSVL3-KO 
U87 cells was not due to different gene expression between the cell lines. It would also 
be important to ensure that differences between GPI anchor levels were not due to 
differences in protein expression. Western blotting or immunofluorescence could be used 
to compare protein expression levels, and immunofluorescence could also be used to 
determine if the proteins were localized to the plasma membrane, as would be expected 
with GPI-anchored proteins. Since no differences were found between GPI anchor levels 
in WT and ACSVL3-KO U87 cells, these experiments were not performed.  
The one commonly GPI-anchored protein that had a difference in mRNA 
expression between WT and ACSVL3-KO U87 cells was ALPL, which was about 5 
times more abundant in WT U87 cells. Consistent with this finding, recent research 
shows that ALPL is upregulated in some aggressive, treatment-resistant glioblastomas 
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(Iwadate et al., 2017). ACSVL3-KO cells are, by many measures, less tumorigenic than 
their WT counterparts, and the lower level of ALPL reflects this phenotype. ALPL is the 
tissue nonspecific (also called liver/bone/kidney) isoform of alkaline phosphatase, but 
there are two other isoforms: intestinal (ALPI) and placental (ALPP). Future directions 
include comparing mRNA levels of these isoforms as well. 
Purified PI-PLC is commercially available. However, it is sold in small quantities 
and seemed to quickly diminish in activity, so we decided to express, purify, and use 
fresh PI-PLC. The enzyme was expressed in E. coli, released by lysis of the bacteria, and 
purified using anion-exchange chromatography on Q-sepharose. PI-PLC expression was 
assessed at several points of the purification process using Coomassie Blue staining, and 
enzyme activity was assessed using a modified Ellman assay. This assay uses PI-PLC to 
cleave the GPI anchors of AchE expressed on erythrocyte membranes, releasing AchE 
into solution. Next, this solution is added to the colorimetric Ellman assay, which 
measures AchE activity. More active PI-PLC will release more AchE, which will lead to 
a higher rate of activity in the Ellman assay. 
The fractions from the purification process that contained putative PI-PLC protein 
by molecular size on gels were found to be enzymatically active in the modified Ellman 
assay. The first supernatant from the bacterial lysis, the first wash of the column, and a 
fraction from the column that was enriched in a 29 kDa protein were each tested. The 
supernatant and column wash had more total PI-PLC than the column fraction, but the 
column fraction had the most PI-PLC activity. This may have been because other proteins 
in the supernatant and wash interfered with PI-PLC or AchE activity, and purification 
removed most of the natural inhibitors.  
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The Ellman assays were attempted with WT U87 cells rather than erythrocyte 
membranes. No increase in absorbance was recorded, indicating that the level of AchE in 
U87 cells is too low to be detected by this assay. This is consistent with the relatively low 
levels of AchE detected in U87 cells via PCR. 
The purification of active PI-PLC was successful, and this enzyme was used to 
digest GPI anchors on protein collected from WT and ACSVL3-KO U87 cells. Total cell 
protein was collected by treating cells with PBS without calcium and magnesium rather 
than trypsin to preserve the GPI-anchored proteins. Protein was transferred to PVDF, 
which was treated with our purified PI-PLC to digest GPI anchors. Finally, the digested 
anchors were detected with α-CRD antibody. There were no apparent differences 
between levels of GPI anchors in WT and ACSVL3-KO U87 cells. This was surprising, 
since two lipid components required to synthesize GPI anchors, PI and PE, were 
synthesized at a lower rate in ACSVL3-KO U87 cells compared to WT U87 cells. This 
may be because GPI anchors occur at a relatively low abundance compared to other post-
translational modifications. Even with the lower rates of lipid synthesis, cells may be able 
to compensate easily. Furthermore, while turnover of GPI anchors occurs by a variety of 
mechanisms and at varying rates, some GPI-anchored proteins, such as Thy-1, turnover 
very slowly (Censullo and Davitz, 1994). In the cases of proteins with very slow rates of 









The covalent attachment of fatty acids to proteins, or acylation, is a post-
translational modification that serves many purposes, including regulating trafficking and 
subcellular location, allowing binding to lipid membranes, and facilitating protein-protein 
interactions. While acylation can occur with fatty acids from 8 to 20 carbons long, the 
long-chain fatty acids myristic and palmitic acids are the most commonly attached fatty 
acids (Resh, 2016). Both the mechanism of acylation and the properties conferred to the 
acylated protein are unique to each fatty acid.  
Palmitoylation is most commonly the thioesterification of palmitic acid to the side 
chain of cysteine, although occasionally it is an amidation of palmitic acid to the side 
chain of lysine (Resh, 2012). This process required palmitoyl-CoA and is a reversible 
modification. Several hundred proteins are known to be palmitoylated (Resh, 2016). The 
enzyme family that attaches the palmitoyl-CoA to the protein is called the DHHC (Asp-
His-His-Cys) family, a group of acyltransferases named after their shared sequence 
(Greaves and Chamberlain, 2010). Palmitoylation has been shown to be critical for 
protein trafficking, membrane anchoring, and lipid raft association. Abnormalities in 
several of the 23 human DHHC proteins have been associated with tumorigenesis, with 
members acting as either tumor suppressors or oncogenes (Yeste-Velasco et al., 2015). 
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We chose to study palmitoylation in WT and ACSVL3-KO U87 cells because of 
its abundance and links to tumorigenesis. However, we also chose to study a much less 
well understood form of acylation, stearoylation, since stearate is preferentially and 
robustly activated by ACSVL3 (Chapter 1). Like palmitate, stearate is also attached to 
cysteine via a thioester linkage (Liang et al., 2002) and is hypothesized to also be 
attached by DHHC enzymes (Resh, 2016). A recent study showed that stearoylation of 
transferrin receptor 1 induces mitochondrial fusion, and providing cells with palmitate 
instead of stearate did not lead to mitochondrial fusion (Senyilmaz et al., 2015). This 
suggests that stearoylation is not simply a substitute for palmitoylation, but confers its 
own distinct properties to proteins to which it is attached.  
A new tool to study protein acylation is click chemistry. Click chemistry is the 
name given to the copper-catalyzed cycloaddition of an azide group to a terminal alkyne, 
allowing two molecules bearing these groups to be covalently linked (Rostovtsev et al., 
2002). Click chemistry-compatible probes have been developed to study fatty acylation 
(Hannoush, 2011). These are fatty acids have the same number of carbons and saturation 
as their naturally-occurring counterparts, except for a ω-alkyne bond. These probes can 
be added to cell culture media, where they are taken up by cells and used in protein 
acylation. After harvesting protein from cells, acylated proteins can be detected by using 
the click reaction. Biotin azide can be used to detect acylated proteins on a membrane 
using streptavidin-HRP, or rhodamine azide can be used to detect acylated proteins via 
in-gel fluorescence. In this study, we used ω-alkynyl-palmitate and ω-alkynyl-stearate to 
study palmitoylation and stearoylation in WT and ACSVL3-KO U87 cells.  
82 
 
Knockdown of ACSVL3 disrupts Akt signaling in glioma cells (Pei et al., 2009). 
Less phosphorylated Akt was detected in response to HGF stimulation when ACSVL3 
was knocked down in U87 cells. These cells also grew more slowly and were less 
tumorigenic, which correlates with the knowledge that Akt signaling promotes cell 
proliferation and survival. One of the kinases inhibited downstream by Akt signaling, 
glycogen synthase kinase 3 (GSK3), promotes degradation of sterol regulatory element-
binding proteins (SREBPs). SREBPs promote fatty acid uptake and biosynthesis, so Akt 
signaling has a positive effect on lipid production (Sundqvist et al., 2005). Our lab has 
demonstrated that ACSVL3 knockdown in U87 cells leads to reduced production of some 
sterols and phospholipids (Kolar, 2016).  We hypothesized that Akt signaling might also 
have a positive effect on protein acylation, and that knock out of ACSVL3 would 
diminish any positive effects induced by Akt.  
In this study, we demonstrated that knockout of ACSVL3 in U87 cells has little 
effect on palmitoylation but does affect stearoylation. We used mass spectrometry to 
characterize some of the changes in stearoylation induced by ACSVL3 knockout. Finally, 
we used EGF to stimulate Akt in WT and ACSVL3-KO U87 cells, and showed that, at 
least over a short time period, this had no effect on protein stearoylation.  
 
Materials and Methods 
 
Immunoblot-like analysis of protein acylation using ω-alkynyl fatty acid probes 
This procedure was modified from the protocols of Rami Hannoush (2011).  
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Preparation of click chemistry probes: 50 mM stock solutions were made of each 
ω-alkynyl-fatty acid probe in DMSO. The stocks were aliquoted and frozen at -80°C until 
used.  
Cell culture: WT and ACSVL3-KO U87 cells were cultured as described in 
Chapter 1. Cells were seeded into 6-well plates in duplicate or triplicate wells and 
allowed to grow to confluence.    
Preparation of cell culture media with click chemistry probes: Serum-free DMEM 
containing 5% fatty acid free BSA was prepared. The media was sonicated at 37°C in a 
water bath type sonicator until all BSA was dissolved and filtered for sterilization. Click 
chemistry probes were diluted to 100 μM in DMEM + 5% BSA. (The equivalent volume 
of DMSO was diluted into media as a negative control.) The media containing probes 
was sonicated for 15 minutes at 37°C in a water bath type sonicator and then allowed to 
rest at room temperature for 15 minutes.  
Treatment of U87 cells with click chemistry probes: Culture media was aspirated 
from the cells. The cells were washed once with PBS and then treated with 1 mL of 
media containing click chemistry probes per well. Cells were incubated for 24 hours. 
Collection of total cellular protein: Probe-containing media was aspirated from 
cells. Cells were washed three times with ice-cold PBS containing calcium and 
magnesium. Each well was then treated with 400 μL of ice-cold lysis buffer comprised of 
100 mM sodium phosphate, 150 mM NaCl, and 1 % Nonidet-P40, as well as fresh 
protease and phosphatase cocktails (Calbiochem). The wells were scraped with sterile 
cell scrapers, cell lysate was transferred to microcentrifuge tubes, and the lysates were 
incubated on a gentle shaker at 4°C for 1 hour. Next, the lysates were centrifuged at 
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16,000g for 10 minutes at 4°C. The supernatant was removed from the pellet (debris) and 
moved to Amicon Ultra 0.5 mL centrifugal filter units (30 kDa NMWL; Millipore 
Sigma). The filter units were centrifuged according to the manual instructions until the 
lysate volume was approximately 100 μL. Protein concentration was determined using 
the Pierce 660 nm Protein Assay (Thermo Fisher Scientific).  
Cycloaddition/click reaction: An aliquot containing 20 μg of protein was placed in 
a microcentrifuge tube and lysis buffer was added to yield a total volume of 23 μL per 
sample. To each sample, the following reagents were added in the following order: 0.5 
μL of 5 mM biotin-azide (BN3), 0.5 μL of 50 mM freshly prepared tris(2-
carboxyethyl)phosphine hydrochloride (TCEP) in H2O, and 0.5 μL of 10 mM tris[(1-
benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA) in DMSO/t-butanol (1:4, v:v). The 
samples were vortexed for 5 seconds. Next, 0.5 μL of freshly prepared 50 mM CuSO4 in 
PBS was added to each sample. Samples were vortexed again for 5 seconds, then 
incubated in the dark for 1 hour.  
The reaction was stopped by adding 250 μL of ice cold acetone to each sample 
and vortexing. Samples were then left at -20°C for at least 2 hours to allow protein to 
precipitate. Finally, the samples were centrifuged at 16,000g for 10 minutes to form a 
protein pellet. The acetone was aspirated and the pellets were left to air dry 
(approximately 10 minutes).  
Blotting: Pellets were resuspended in with agitation in 24 μL of lysis buffer and 6 
μL of 5X SDS gel running buffer (described in Chapter 1, “Western blotting”). Samples 
were boiled for 5 minutes then separated using SDS-PAGE. Proteins were transferred to 
PVDF membrane as described in Chapter 1. The membrane was incubated for 1 hour in 
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10% milk in TBST to block, rinsed 3 times with TBST, and washed 5 times for 10 
minutes in TBST. Next, the membrane was incubated in streptavidin-horseradish 
peroxidase (HRP) diluted 1:80,000 in TBST. Again the membrane was rinsed 3 times 
with TBST and washed 5 times for 10 minutes in TBST. Finally, the membrane was 
incubated in SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher 
Scientific) according to the reagent manual’s instructions and exposed to film to detect 
signal.  
 
Treatment of U87 cells with EGF  
EGF treatment time course: WT and ACSVL3-KO U87 cells were seeded into 6-
cm dishes and allowed to grow to confluency. Cell media was aspirated and replaced 
with media containing 0.1% FBS (low serum media) overnight to serum starve the cells 
prior to EGF treatment. Cells were then treated with low serum media with 0.2 mM 
epidermal growth factor (EGF) for 0, 0.5, 1, 2, or 24 hours. Cells were lysed with 150 μL 
ice-cold radioimmunoprecipitation assay (RIPA) buffer (25 mM Tris-HCl pH 7.6, 150 
mM NaCl, 1% NP-40, 1% sodium deoxycholate, and 0.1% SDS) with protease inhibitors 
(Calbiochem) and scraped to collect. Protein concentration was measured using the assay 
described by Lowry et al. (1951). 30 μg of total protein from each sample was separated 
using SDS-PAGE. Western blotting was performed as described in Chapter 1 with the 
primary antibodies α-Akt, α-phospho-Akt (Ser473), and α-phospho-S6 (Ser240/244; all 
from Cell Signaling Technology). All antibodies are rabbit polyclonal antibodies diluted 
1:1000 in milk solution. The secondary antibody was goat α-rabbit IgG-HRP (1:8000 
dilution in milk solution). 
86 
 
Concurrent treatment of U87 cells with EGF and ω-alkynyl-stearic acid probe: 
WT and ACSVL3-KO U87 cells were cultured and seeded into 6-well plates as described 
in the previous section. Once confluent, cells were serum-starved with low serum media 
for 1 hour. Next, this media was aspirated and replaced with DMEM containing 5% BSA, 
100 μM stearic acid probe, and 0.2 mM EGF. Cells were incubated for 2 hours. Cells 
were lysed, protein was collected, and the click reaction and blotting were performed as 
described in the previous section.  
 
Mass spectrometry of stearoylated proteins 
Preparation of stearoylated protein: Cells were seeded into 6-well plates and 
cultured as described previously. 5 wells each of WT and ACSVL3-KO U87 cells were 
set up, 4 replicates and one negative control for both cell lines. (The negative control 
cells were treated with media that did not contain the ω-alkynyl fatty acid probe).  The 
cells were treated and collected as described previously. The click reaction was 
performed with 3 times the previously used volumes of all reagents (75 μL instead of 25 
μL total), amounting to 43 μg of protein per sample. Instead of stopping the reaction with 
acetone, the lysis buffer was exchanged to remove unreacted reagents. This was done by 
transferring the reaction volume to an Amicon Ultra 0.5 mL centrifugal filter unit (30 
kDa NMWL; Millipore Sigma) and adding 250 μL of lysis buffer. The filter units were 
centrifuged at 14,000g for approximately 5 minutes, or until the total volume in the unit 
was approximately 100 μL. Next, 250 μL of lysis buffer was again added to the column, 
and the column was again centrifuged at 14,000g until approximately 100 μL remained. 
This process was repeated a total of 5 times.  
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Precipitation and washing: After the buffer exchange, the lysates were moved 
from the filter units to microcentrifuge tubes. 200 μL of lysis buffer was added to to each 
sample for a total volume of approximately 300 μL. 15 μL of streptavidin agarose resin 
slurry (Thermo Fisher Scientific) was added to each lysate. The samples were turned end-
over-end for 1 hour at room temperature in order for the streptavidin beads to bind with 
biotinylated proteins. Afterwards, the beads and lysate were transferred to Ultrafree-MC 
0.45 μm filter units (Millipore Sigma). The tubes were centrifuged at 12,000g to separate 
lysate from the beads. 300 μL of 100 mM sodium phosphate with 150 mM NaCl (the 
same composition as lysis buffer without detergent) was added to the beads to wash away 
unbound proteins. The filter units were agitated gently to mix, and then centrifuged at 
12,000g for 1 minute. This process was repeated for 5 total washes. After the final wash, 
the beads were resuspended in 200 μL 100 mM sodium phosphate/150 mM NaCl and 
transferred to microcentrifuge tubes. The tubes were centrifuged for 1 minute and excess 
buffer was aspirated. Just enough buffer was left so the beads would not dry out. The 
samples were frozen at -80°C until mass spectrometry analysis. 
Preparation of peptides for mass spectrometry: Beads were prepared, proteins 
were digested, and mass spectrometry was performed by the Johns Hopkins Mass 
Spectrometry and Proteomics Core directed by Robert N. Cole, PhD.  The pH of the 
beads in buffer was adjusted by adding 2 μL 500mM triethylammonium bicarbonate 
(TEAB) to each sample. Proteins were reduced by treating each sample with 2 μL of 
iTRAQ TCEP (SCIEX) and incubating at 60°C for 1 hour, then alkylated by incubating 
each sample with 1 μL of methyl methanethiosulfonate for 15 min at room temperature. 
To remove any proteins pulled down due to protein-protein interactions from the beads, 
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the following wash was performed to each set of beads 3 times: 40 μL of 50 mM TEAB 
was added to each sample, the beads were centrifuged briefly, and supernatant was 
discarded. To digest proteins remaining on the beads, beads were incubated overnight at 
37°C with 800 ng of trypsin in 50mM TEAB. Peptides were collected by washing each 
set of beads 3 times with 100 μL of 50% acetonitrile/0.1% trifluoroacetic acid (TFA), 
saving and combining the supernatants from each wash. Each sample was dried down and 
then reconstituted in 30 μL TEAB. Each sample was labeled with 2.5 μL of Tandem 
Mass Tag (TMT) 10-plex (Thermo Fisher Scientific), split into 2 aliquots, and dried. One 
aliquot from each sample was fractionated using basic reversed-phase peptide 
fractionation using Oasis PRiME HLB 96-well plates (Waters). To perform this 
fractionation, the samples were resolubilized 3 times in 150 μL 0.1% TFA and loaded 
onto the plates, then eluted with 10mM TEAB containing the following increasing 
percentages of acetonitrile: 5%, 15%, 20%, 30%, 75%. The fractions were split into two, 
and one half of each fraction was dried and reconstituted in 20 μL 2% acetonitrile/0.1 % 
TFA. 5 μL of each reconstituted fraction was used for liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) analysis.  
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis: 
Samples were analyzed by tandem MS using a nano-LC-Orbitrap-Fusion in FTFT 
(Thermo Fisher Scientific) interfaced with Easy-LC system (Waters). The LC component 
used reversed-phase chromatography (2%-90% acetonitrile/0.1% FA gradient over 105 
min at 300 nl/min) on 75 μm x 150 mm ProntoSIL C18-EPS (particle size 5 μm) columns 
(BISCHOFF). Eluted proteins were sprayed into the mass spectrometer through a 1 μm 
emitter tip (New Objective) at 2.0 kV. Survey scans were acquired on the Orbitrap from 
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380-1700 Da m/z using data-dependent acquisition with a Top15 method with a dynamic 
exclusion time of 30 seconds. Precursor ions were individually isolated with 1.0 Dalton 
window, then fragmented using higher-energy collisional dissociation (HCD) 
fragmentation using a normalized collision energy of 35%. Precursor and HCD 
fragmentation ions were analyzed at resolution settings of 60,000 and 120,000. The AGC 
target value was set to 3 × 10
6
 at a maximum ion accumulation time of 50 ms.  
Data analysis: Spectra were processed in Proteome Discoverer version 2.2 
(Thermo Fisher Scientific) using 2Nodes by both common processing and Xtract. When 
using Xtract, spectra are extracted, charge state deconvoluted, and deisotoped at a 
resolution of 85K at 400 Da. MS/MS spectra from 2Nodes were analyzed with Mascot 
Server version 2.5.1. (Matrix Science) using 2015RefSeq_72r_human_plus (with added 
enzyme and BSA for quality control) with the following specifications: all species, 
trypsin as the enzyme, 2 allowed missed cleavage sites, precursor mass tolerance of 10 
ppm, fragment mass tolerance of 0.02 Da, methylthio groups attached to cysteine, TMT 
6-plex attached to N-termini, and the variable modifications of oxidation of methionine, 
deamidation of N and Q, and TMT 6-plex attached to lysine. Peptide identifications from 
Mascot searches were processed within Proteome Discoverer version 2.2 using Target 
Decoy Peptide-Spectrum Match Validator both to identify peptides with a confidence 
threshold 1% False Discovery Rate based on a concatenated decoy database search and to 
calculate the protein and peptide ratios. The following settings were used in the Reporter 
Ions Quantifier Node: the normalization mode “Total Peptide Amount”, the scaling mode 
“On All Average”, the ratio calculation “Summed Abundance Based”, and the ANOVA 






Protein palmitoylation is similar between WT and ACSVL3-KO U87 cells, but 
stearoylation is reduced in ACSVL3-KO U87 cells 
The products of the acyl-CoA synthetase reaction catalyzed by ACSVL3 can 
generate substrates such as palmitoyl-CoA and stearoyl-CoA that can potentially acylate 
proteins. To assess this possibility, we examined the differences in protein palmitoylation 
and protein stearoylation in WT U87 glioma cells and cells lacking ACSVL3. Terminal-
alkyne palmitate and stearate were added to cell media and allowed to incorporate into 
WT and ACSVL3-KO U87 cells. Cell protein was collected and was used in a “click” 
reaction, which is a copper-catalyzed cycloaddition of azide- and alkyne-bearing 
molecules. In this case, the terminal-alkyne fatty acids reacted with biotin azide so that 
following the reaction, palmitoylated or stearoylated proteins are then biotinylated. After 
the reaction, proteins were separated by SDS-PAGE and transferred to PVDF. To detect 
acylated proteins, a technique similar to a Western blot was used. Instead of antibodies, 
PVDF membranes were incubated in a solution containing streptavidin-HRP. The 
streptavidin bound to the biotinylated (and therefore acylated) proteins, and HRP 
catalyzed a chemiluminescent signal used to visualize acylated protein bands. This 
process is illustrated in Figure 21a.  
    Using this technique, the palmitoylation profiles of WT and ACSVL3-KO U87 cells 
appear very similar (Figure 21b). However, the stearoylation profiles of the 2 cell lines 
are different. In general, protein stearoylation appears reduced in ACSVL3-KO U87 cells 
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compared to WT U87 cells (Figure 21c). However, when comparing proteins band-by-
band, some appear to have increased intensity and some appear to have decreased 
intensity, suggesting that stearoylation changes in ACSVL3-KO U87 cells compared to 






Akt signaling in WT U87 cells responds similarly to EGF as to HGF 
Previously published data showed that when U87 cells were treated with HGF, 
phospho-Akt (pAkt) levels rose over the next few hours, peaking around 2 hours, and 
Figure 21: Detection of acylated proteins in WT and ACSVL3-KO U87 cells 
 
A. Illustration of the click chemistry reaction. Cellular proteins are acylated by 
culturing cells in the presence of terminal alkyne probes (ω-alkynyl-fatty acids). Cells 
are lysed and protein is collected and used in the click reaction with biotin azide. The 
azide group in biotin azide reacts with the terminal alkyne of acylated proteins through 
a cycloaddition, thus linking biotin to acylated proteins. These proteins can be 
detected on a membrane using streptavidin-HRP or pulled down using streptavidin-
linked agarose beads. B. Palmitoylation of proteins from WT and ACSVL3-KO U87 
cells was detected with streptavidin-HRP. The palmitoylation pattern appears very 
similar between the cell lines. C. Stearolyation of proteins from WT and ACSVL3-KO 
U87 cells were detected in the same manner. There appear to be many differences 
between the two cell lines. Overall, stearoylation appears decreased in ACSVL3-KO 
cells, but stearoylation of some proteins appear increased and others decreased 
between the cell lines.  
93 
 
remained elevated after 24 hours (Pei et al., 2009). Total Akt varied slightly, but not as 
dramatically, over the same time frame. To determine if EGF would have similar effects 
on WT U87 cells, cells were treated for most of the same time points, and pAkt and total 
Akt levels were assessed by Western blots. The blots revealed a similar rise in pAkt 
levels over the course of 2 hours (Figure 22). At 24 hours, the pAkt level had dropped 
from its level at the 2-hour time point, but remained elevated over its initial, pre-EGF 
treatment level. (In fact, the pAkt level prior to EGF treatment was undetectable on this 
Western blot.) Total Akt also rose somewhat over the first 2 hours of EGF treatment, and 
appeared to have returned to its pre-EGF treatment level by 24 hours. In general, EGF 
had a similar, excitatory effect on WT U87 cells as HGF. 
 
 
Akt signaling in response to EGF is disrupted in ACSVL3-KO cells  
When ACSVL3 was knocked down using RNAi, pAkt did not increase in 
response to HGF. It decreased over 2 hours and then returned to approximately initial 
levels by 24 hours (Pei et al., 2009). To determine if ACSVL3-KO U87 cells respond 
similarly to EGF treatment, both WT and ACSVL3-KO cells were treated with EGF. 
Figure 22: Activation of Akt by EGF in U87 cells 
 
Phosphorylation of Akt (p-Akt) was seen after the addition of EGF to U87 cells, 
peaking 2 hours after EGF treatment, and remaining slightly elevated after 24 hours. 
Total Akt also rose, but not as dramatically. Akt signaling in U87 cells responds 
similarly to EGF treatment as it does to HGF treatment.  
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Cells were collected at 3 time point: 0, 0.5, and 2 hours. As expected, pAkt rose over the 
time points in WT U87 cells. (Figure 23) Although there is high background on the 
Western blot, pAkt did not appear to rise over the time points in ACSVL3-KO U87 cells. 
This indicates that, as expected, the knockout of ACSVL3 disrupts EGF-incited Akt 
signaling in U87 cells.  
    Since S6K is activated in response to Akt signaling in glioblastomas (Riemenschneider 
et al., 2006), phosphorylated S6 was also detected in WT and ACSVL3-KO U87 cells 
using Western blotting. Its level rose over the time points in both cell lines, although it 
appeared to rise more dramatically in WT U87 cells than in ACSVL3-KO cells. 
 
 
EGF does not affect short-term protein stearoylation in WT or ACSVL3-KO U87 
cells 
To determine if stearoylation changed in response to Akt signaling, and to 
determine if stearoylation would respond differently to Akt signaling in WT and 
Figure 23: Comparison of activation of Akt by EGF in WT and ACSVL3-KO 
U87 cells 
 
Phosphorylation of Akt (p-Akt) rose over 2 hours after EGF treatment in WT U87 
cells, but not in ACSVL3-KO U87 cells. Phosphorylation of S6 (p-S6), a downstream 
target of the Akt signaling pathway, rose more dramatically in WT U87 cells than in 
ACSVL3-KO U87 cells. This data indicates that knockout of ACSVL3 disrupts EGF-
induced Akt signaling. 
95 
 
ACSVL3-KO U87 cells, both cell lines were treated concurrently with EGF and ω-
alkynyl-stearate. Cells were collected after 2 hours, and stearoylated proteins were 
detected using the streptavidin-HRP based, Western blot-like technique described earlier. 
Stearoylation did not appear to change in response to EGF in either WT or ACSVL3-KO 
U87 cells (Figure 24). Furthermore, there was no apparent difference in stearoylation 




Figure 24: Stearoylation of proteins in WT and ACSVL3-KO U87 cells 
stimulated with EGF 
 
WT and ACSVL3-KO U87 cells were treated simultaneously with ω-alkynyl-stearate 
and EGF for two hours. Stearoylation was evaluated by submitting proteins from each 
cell sample to the click reaction, separating proteins by SDS-PAGE, and detecting 
stearoylated proteins with streptavidin-HRP. EGF did not appear to affect 
stearoylation of proteins in either cell line. Furthermore, stearoylation did not appear 
to differ between WT and ACSVL3-KO U87 cells in this experiment, indicating that 
the differences in stearoylation between the two cell lines arise between 2 and 24 
hours of incubation with ω-alkynyl-stearate.  
96 
 
Upregulated and downregulated stearoylation of proteins identified by mass 
spectrometry 
Because of the complex variation of protein stearoylation between WT and 
ACSVL3-KO U87 cells, mass spectrometry was used to identify specific stearoylated 
proteins and quantify their amounts in both cell lines. WT and ACSVL3-KO U87 cells 
were treated with terminal-alkyne stearic acid. Protein was collected and used in click 
reactions to biotinylate stearoylated proteins. These proteins were then pulled down using 
streptavidin agarose resin, then digested and subjected to mass spectrometry.  
Nine stearoylated proteins were identified as significantly more abundant in WT 
U87 cells than in ACSVL3-KO U87 cells (p < 0.05). Despite global stearoylation 
appearing to be down regulated in ACSVL3-KO U87 cells compared to WT U87 cells, 
37 stearoylated proteins were identified as significantly more abundant in ACSVL3-KO 
U87 cells compared to WT U87 cells (p < 0.05). These proteins are listed in the tables 
below. Of all the proteins identified (over 1200), approximately the same number of 
proteins were upregulated and downregulated in ACSVL3-KO U87 cells compared to 
WT U87 cells if. A number of stearoylated proteins were detected only in WT U87 cells 
and so relative abundance could not be calculated. However, these proteins may be of 
interest because they may be stearoylated only in WT U87 cells.  
In each of the tables below, proteins in bold were assigned high confidence by 
Mascot analysis. The second column lists the ratios of the abundances of stearoylated 
proteins in WT vs ACSVL3-KO U87 cells. Mass spectrometry of stearoylated proteins 
was cross-referenced with a total proteomic analysis described by Kolar (2016). The 
ratios of the abundances of total WT and ACSVL3-KO U87 proteins are listed in the 
97 
 
third column. Ratios in red represent ratios that showed upregulation in stearoylation, but 
downregulation in total protein. “ND” refers to proteins not detected in MS analysis. 




Table 3: Stearoylated proteins more abundant in WT U87 cells vs. ACSVL3-KO 
U87 cells 
 







immortalization up-regulated protein (IMUP) 2.4 ND 
plastin-3 isoform X1 (PLS3) 2.4 ND 
heat shock 70 kDa protein 1A/1B 
(HSPA1A; HSPA1B) 
2.1 0.7 
14-3-3 protein zeta/delta isoform X1 
(YWHAZ) 
1.8 0.6 
moesin isoform X1 (MSN) 1.8 ND 
plasminogen activator inhibitor 2 
(SERPINB2) 
1.8 0.2 
14-3-3 protein epsilon (YWHAE) 1.7 0.5 
glutathione S-transferase P (GSTP1) 1.6 0.4 
platelet-activating factor acetylhydrolase IB 
















CD81 antigen isoform 1 (CD81) 5.2 ND 
transmembrane 4 L6 family member 1 
(TM4SF1) 
4.1 ND 
CD9 antigen (CD9) 4.0 1.2 
alpha-2-macroglobulin isoform X1 (A2M) 3.8 ND 
CD59 glycoprotein preproprotein (CD59) 3.4 0.2 
dnaJ homolog subfamily C member 5 
isoform X1 (DNAJC5) 
3.4 ND 
poliovirus receptor isoform alpha precursor 
(PVR) 
3.4 ND 
SH3 domain-binding glutamic acid-rich-like 
protein 3 (SH3BGRL3) 
3.4 2.1 
7,8-dihydro-8-oxoguanine triphosphatase 
isoform p22 (NUDT1) 
3.2 ND 
tetraspanin-4 isoform X3 (TSPAN4) 3.1 0.5 
5'-nucleotidase isoform 1 preproprotein 
(NT5E) 
3.0 0.9 
CD151 antigen (CD151) 3.0 0.4 
integrin alpha-2 precursor (ITGA2) 3.0 1.3 
reticulon-3 isoform X1 (RTN3) 2.9 ND 
transgelin-2 isoform a (TAGLN2) 2.8 ND 
nicastrin isoform 1 precursor (NCSTN) 2.7 ND 
glycolipid transfer protein (GLTP) 2.7 ND 
adenine phosphoribosyltransferase isoform a 
(APRT) 
2.5 ND 
bcl-2-like protein 1 isoform X1 (BCL2L1) 2.5 ND 





phospholipase D3 isoform X1 (PLD3) 2.3 1.9 
B-cell receptor-associated protein 31 
isoform a (BCAP31) 
2.3 ND 
transaldolase (TALDO1) 2.3 4.6 
protein kish-A precursor (TMEM167A) 2.2 ND 
astrocytic phosphoprotein PEA-15 isoform a 
(PEA15) 
2.2 ND 
ATP synthase subunit g, mitochondrial 
(ATP5L) 
2.2 0.9 
transmembrane protein 14C (TMEM14C) 2.1 0.8 
ATP synthase F0 subunit 6, mitochondrial 
(ATP6) 
2.1 0.6 
ras-related protein Rab-14 (RAB14) 2.1 0.7 
FUN14 domain-containing protein 2 
(FUNDC2) 
2.0 1.5 
CAAX prenyl protease 1 homolog 
(ZMPSTE24) 
1.9 1.1 
voltage-dependent anion-selective channel 
protein 3 isoform 2 (VDAC3) 
1.9 ND 
p53 apoptosis effector related to PMP-22 
(PERP) 
1.9 ND 
aspartate aminotransferase, cytoplasmic 
(GOT1) 
1.8 2.9 
cytosol aminopeptidase (LAP3) 1.8 1.2 
ATP synthase subunit d, mitochondrial 
isoform a (ATP5H) 
1.7 0.6 









    The purpose of this study was to determine if ACSVL3 is involved in the acylation of 
proteins, as this approach might identify novel cancer targets. Because acylation requires 
the fatty acids to be activated by an acyl-CoA synthetase, we hypothesized that acylation 
of long-chain fatty acids would be reduced in ACSVL3-KO U87 cells compared to WT 
U87 cells. Furthermore, many of the DHHC enzymes, which catalyze the transfer of 
palmitoyl-CoA and likely stearoyl-CoA to cysteine residues within proteins, are 
implicated in tumorigenesis (Yeste-Velasco et al., 2015). We hypothesized that changes 
in long chain acyl-CoA levels caused by upregulated ACSVL3 in tumor cells are tumor-
promoting as well. 
    To study acylation in cell cultures, we used click chemistry-compatible probes: fatty 
acids identical to palmitic and stearic acid except for a terminal alkyne bond between the 
final two carbons (a ω-alkynyl bond). Using an alkyne group preserved the neutral, 
hydrophobic nature of the fatty acids and hopefully allowed them to be trafficked normal 
within the cells. However, the alkyne group also conferred reactivity to the fatty acids. 
After protein was collected, the click reaction, a cycloaddition of biotin azide and the 
alkyne group at the end of the fatty acids. This reaction biotinylated proteins that had 
been acylated in the cells, allowing them to be detected with streptavidin-HRP on a 
membrane or pulled down from a whole cell lysate using streptavidin beads.  
First, we used a Western blot-like analysis to compare palmitoylation and 
stearoylation in WT and ACSVL3-KO U87 cells. Palmitoylation was not significantly 
changed , but stearoylation was. Overall, stearoylation was decreased in ACSVL3-KO 
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U87 cells compared to WT U87 cells, but it appeared that some proteins had increased 
stearoylation and others had decreased stearoylation when ACSVL3 was knocked out. 
The general trends aligned with our findings of the preferred substrates of ACSVL3, 
discussed in Chapter 1. Like palmitoylation, the activation of palmitic acid was not 
significantly reduced in ACSVL3-KO U87 cells, and like stearoylation, activation of 
stearic acid was reduced in ACSVL3-KO cells compared to WT U87 cells. The variation 
of protein stearoylation between WT and ACSVL3-KO U87 cells led us to use mass 
spectrometry to identify stearoylated proteins and determine which are upregulated and 
downregulated in response to ACSVL3 knock-out.  
Consistent with the immunoblot-like data, some proteins appeared to have 
increased stearoylation and others appeared to have decreased stearoylation in ACSVL3-
KO U87 cells compared to WT U87 cells as detected by mass spectrometry. However, 
while the immunoblot-like data suggested a global decline in stearoylation with ACSVL3 
knockout, MS data revealed approximately equal numbers of upregulated and 
downregulated stearoylated proteins, and more statistically significant downregulated 
stearoylated proteins. As expected, many of the proteins identified that showed up- or 
down-regulated stearoylation also exhibited up- or down-regulation of total protein. 
However, a few proteins exhibited upregulated stearoylation with ACSVL3 knockout but 
a decrease in total protein, or, conversely, an increase in total protein but a decrease in 
stearoylation with ACSVL3 knockout. These proteins are targets of interest for future 
experiments. One interesting takeaway from the MS data is that three subunits of ATP 
synthase were stearoylated, and stearoylation of each was increased in ACSVL3-KO 
cells. Our lab has shown that knockout of ACSVL3 disrupts mitochondrial function, and 
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that ACSVL3-KO U87 cells have less ATP synthase than WT U87 cells (Kolar, 2016). 
Perhaps stearoylation is a negative regulator of ATP synthase, or somehow regulates its 
function.  
We wanted to determine if Akt stimulation via EGF would affect stearoylation, 
but first we had to determine if EGF-stimulated Akt signaling was disrupted by ACSVL3 
knockout. Previously, it was shown that Akt signaling through another receptor tyrosine 
kinase, c-Met, was disrupted with RNAi knockdown of ACSVL3 (Pei et al., 2009). In 
those studies, Akt signaling was stimulated by the c-Met ligand, hepatocyte growth factor 
(HGF), so we demonstrated that EGF stimulation elicited a similar response in WT U87 
cells. Next, we demonstrated that knockout of ACSVL3 had a similar effect on Akt 
signaling as stable knockdown of ACSVL3. The highest level of pAkt in WT U87 cells, 
and the biggest difference in pAkt levels between WT and ACSVL3-KO U87 cells, 
occurred at 2 hours after the addition of EGF. Based on this finding, we added stearate 
probes and EGF simultaneously and collected cell protein after 2 hours, and then used 
blotting to compare stearoylation of proteins from WT and ACSVL3-KO U87 cells both 
with and without EGF treatment. EGF treatment did not lead to differences in 
stearoylation in either cell line. However, this is not sufficient to conclude that EGF does 
not affect stearoylation. While Akt phosphorylation peaks at 2 hours after EGF treatment, 
protein acylation could peak later. Also, as discussed earlier, Akt upregulates de novo 
synthesis of lipids, and newly-synthesized fatty acids were used in acylation; the 
detection of click-compatible probes would not reflect this. Surprisingly, no differences 
in stearoylation were seen in the control (no EGF treatment) WT and ACSVL3-KO U87 
cells after 2 hours. Since differences in stearoylation occurred after 24 hours of treatment, 
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a time course will be done to see when these differences arise. This will help determine 
the ideal length of treatment with EGF in future experiments.  
A shortcoming of using blotting and mass spectrometry to assess levels of 
acylation is that changes in band intensity between samples could reflect not only 
changes in acylation, but also changes in protein level. While the same total amount of 
protein was loaded onto gels used for blotting, there is no way to control for individual 
protein levels. We know from independently obtained proteomic data that several 
proteins exhibit different expression levels between WT and ACSVL3-KO U87 cells 
(Kolar, 2016; unpublished data). When individual proteins are identified to have different 
levels of acylation between the two cell lines, protein level will be assessed as well, either 
by cross-referencing to proteomic data or by western blotting. However, acylation could 
affect protein level either positively (eg. by promoting stability) or negatively (eg. by 
targeting the protein for endocytosis and degradation). Therefore, the purpose of 
acylation of individual proteins must be studied as well, making this a very interesting 
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 ASBMB Graduate Student Travel Award (2017): Awarded $1,000 
from the American Society of Biochemistry and Molecular Biology to 
travel to and present at the annual Experimental Biology conference in 
Chicago, IL. 
 
 Johns Hopkins School of Medicine Core Coins in Proteomics grant: 
Received $4,000 towards proteomic services to study protein 




   
 
Investigation of the mechanism of Acyl-CoA Synthetase Very Long Chain 3 
(ACSVL3) in human glioma 
 Helped to generate an ACSVL3 knock-out human glioblastoma cell 
line. 
 Studied effect of EGF on Akt signaling and stearoylation in WT and 
ACSVL3-KO cells. 
 Studied difference in total cellular acyl-CoA synthetase activity in WT 
and ACSVL3-KO cells. 
 Studied expression of GPI-anchored proteins in WT and ACSVL3-KO 
cells.  
 Studied differences in protein acylation (especially stearoylation) in 






Search for and characterization of ACSVL3 inhibitors  
 Tested known inhibitors of ACSVL1, a homologous enzyme, for 
inhibition of acyl-CoA synthetase activity in WT and ACSVL3-KO 
cells. 
 Helped to develop a screen to identify new inhibitors of ACSVL3.  
 Characterized the effects of a potent inhibitor, CB5, on cell growth 
rate and invasiveness of glioma cells.  
 Studying the effect of CB5 on cell differentiation and tumor growth in 
cells in culture and mice bearing xenograft tumors.  
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Search for plasma-based biomarkers of preeclampsia and preterm birth  
 Analyzed mass spectrometry readings to find significant peptides 
associated with preeclampsia and preterm birth 
 Analyzed data for significance and reported statistics for patent 
consideration 
 Prepared samples for analysis on mass spectrometer 
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 Undergraduate Intern, Spectrum Laboratories, Coeburn VA, 2008  
 
 Performed thermogravimetric analysis, acid-base titrations, and 
constant volume calorimetry on hundreds of coal and soil samples 
 Analyzed data 
 Prepared report forms for over 50 clients  
 Revised standard operating procedures and wrote a standard operating 
procedure for temperature regulation 
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 Volunteer Team Leader for Thread, 2010-2017: mentored high school 
and college students in Baltimore, organized a team of volunteers 
working several students for 3 years, planned events, and recruited 





 Hopkins Marathon Team Captain, 2013-2015: Organized workouts and 
events for several dozen students at Johns Hopkins University as they 
trained for marathons and half marathons, applied for and managed all 
group funding, and served as an Organization Representative to the 
Johns Hopkins School of Medicine Graduate Student Organization 
 
 Volunteer for Student Outreach Program, 2013-2014: Designed 





 grade students enrolled in after school and summer enrichment 
programs 
 
